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GENERAL INTRODUCTION 
Arsenic is a non-metal or metalloid in Group V of the 
Periodic Table but is referred to as "arsenic metal". 
Predominant valences for arsenic are +3 and +5. Naturally 
occurring arsenic is usually pentavalent and arsenic added to 
the environment is trivalent (Hammond and Beliles, 1980). 
Arsenic combines with numerous elements in nature and is 
rarely present as a free element. Arsenic is ubiquitous and 
is present in rock, soil, water, and living organisms. Man's 
activities can add significant amounts of arsenic to the 
environment. Contamination sources include smelter and 
fossil fuel burning power plant stack emissions, pesticides, 
and cotton desiccants (Piver, 1983; Fitzgerald, 1983). 
It is impossible for animals or man to avoid exposure to 
natural sources of arsenic. Because of arsenic's ubiquitous 
nature all food sources contain some arsenic. In addition to 
natural sources, the frequent use of arsenicals as herbicides 
creates the potential for accidental exposure to higher 
concentrations of arsenic. High level exposures result in 
dramatic clinical signs and high morbidity. Lesions of acute 
poisoning are well documented (Sullivan, 1985; Osweiler et 
al., 1985; NAS, 1977). Much of the information on chronic 
effects of arsenic exposure is from epidemiological studies 
in man. These studies include many uncontrolled factors that 
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could enhance, inhibit, or obscure the true effects of 
arsenic. This controlled experimental study was designed to 
determine at what concentration dietary arsenic causes 
adverse effects in dogs and what these effects are. 
Numerous subchronic and chronic arsenic studies have 
been done with rats and a lesser number with mice (Byron et 
al., 1967; Schroeder and Balassa, 1967; Schroeder et al., 
1968; Kiyono et al., 1974; Fowler et al., 1979b; Fowler and 
Woods, 1979). A need for chronic studies in higher animals 
exists. This is especially true since it has been found that 
rats metabolize arsenic differently than any other species 
studied (Vahter, 1983). 
Only two chronic inorganic arsenic feeding studies in 
dogs have been done. Calvery et al. (1938) reported no 
clinical effects in dogs given feed containing up to 107.5 
ppm arsenic as arsenic trioxide. Byron et al. (1967) fed 
dogs a diet containing 5.0 to 125 ppm of arsenic as sodium 
arsenate or sodium arsenite. The sodium arsenite high dose 
group lost 44 to 61 percent of its initial body weight. The 
sodium arsenate high dose group had less dramatic but 
significant weight loss. These studies left a need for a 
more detailed and comprehensive investigation. Close 
examination of feed intake, body weight, arsenic intake, and 
pathological changes (clinical and morphological) were not 
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available. 
Hepatocyte ultrastructure has been morphologically 
evaluated in arsenic exposed rats and mice. Rats chronically 
exposed to sodium arsenate had significant increases in 
mitochondrial volume density and surface density of the inner 
mitochondrial membrane (Fowler et al., 1979b). Mice with a 
similar sodium arsenate exposure had no statistically 
significant hepatocyte ultrastructural changes (Fowler and 
Woods, 1979). No morphological study of hepatocyte 
ultrastructure of dogs or higher animals has been done. 
There is no information whether canine hepatocytic 
mitochondria react similarly to rat or mouse mitochondria, or 
differently altogether. 
The objectives of this study were to; 
1. Establish chronic toxic and tolerated dosages of 
sodium arsenite in dogs. 
2. Establish the effect of dietary sodium arsenite on 
feed intake and body weight. 
3. Evaluate hematologic, serum chemistry, and urinary 
effects in dogs chronically exposed to dietary sodium 
arsenite. 
4. Morphologically and stereologically evaluate the 
ultrastructure of arsenic exposed canine hepatocytes. 
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Explanation of Dissertation Format 
This dissertation is presented in the format of 
Toxicology and Applied Pharmacology and consists of multiple 
manuscripts which will be submitted to Toxicology and Applied 
Pharmacology. 
The general introduction and literature review precede 
the first manuscript. A summary and discussion follows the 
last manuscript. A list of references appears at the end of 
each manuscript. Literature cited in the general 
introduction, literature review, and summary and discussion 
appears at the end of the dissertation. 
The Ph.D. candidate, Regg Neiger, was the principal 
investigator for each study. 
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LITERATURE REVIEW 
Chemical Nature of Arsenic 
Arsenic is a member of Group V of the Periodic Table of 
elements. Its chemical symbol is As, atomic number 33 and 
atomic mass weight 74.91. There are five electrons in 
arsenics outer shell, two in the s orbit and three in the p 
orbit. Possible valences are -3, 0, +3, and +5. However the 
+3 and +5 are dominant. Arsenic is a non-metal or metalloid 
but is referred to as "arsenic metal". 
It is rare to find elemental arsenic free in the natural 
environment. Arsenic combines with many elements besides 
oxygen and hydrogen including sulfur, nickel, cobalt, copper, 
iron, aluminum, barium, bismuth, calcium, lead, magnesium, 
manganese, uranium, and zinc. In one of its many forms 
arsenic can be found in rocks, soils, water, and living 
organisms in concentrations of parts per million or billion 
(NAS, 1977). 
The National Academy of Science (1977) reviewed arsenic 
and its chemistry. Following is the grouping of the 
inorganic arsenic compounds, and their chemistry, considered 
of environmental importance. 
Arsenic trioxide (ASgO^) is also referred to arsenious 
acid anhydride or "white arsenic". It is the primary product 
of arsenic smelters and is formed by the roasting of metallic 
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arsenides of arsenic containing sulfides. It is 
unintentionally formed by the burning of coal containing 
arsenic. Arsenic trioxide is slightly soluble in water, 
sublimes at 135° C and melts at 272°C. This compound has 
direct industrial uses and is the primary ingredient in the 
formation of many organic and inorganic arsenicial 
derivatives (NAS, 1977). A few direct applications, some 
which are obsolete, are; insect and fungus control, glass and 
paint production, and timber preservation (Kipling, 1977). 
Arsenic pentoxide (ASgOg) is formed by the oxidation of 
elemental arsenic or arsenic trioxide by nitric acid. This 
compound is very soluble in water (NAS, 1977). It has been 
used as a chemical intermediate, defoliant and wood 
preservative (Kipling, 1977). 
Arsenous acid (H^AsOg) and arsenic acid (H^AsO^) can be 
produced from arsenic trioxide being dissolved in water or 
nitric acid respectively (NAS, 1977). 
Arsenites of the formulas MHgAsO^, MgHAsO^, and M^AsO^ 
are known. M is a univalent metal cation, or one equivalent 
of a multivalent cation (NAS, 1977). The character of the 
cation determines the solubility of the compound in water. 
Alkali-metal arsenites are freely soluble, alkaline-earth 
arsenites slightly soluble, and heavy-metal arsenites 
insoluble. Sodium meta-arsenite, NaAsOg, can be manufactured 
7 
from arsenious oxide and caustic soda with a little water 
(Buchanan, 1962). Sodium meta-arsenite like other alkali-
metal arsenites is highly soluble in water. 
A few common arsenates are calcium arsenate 
[Ca^(AsO^)2]/ lead arsenate [Pb^(AsO^)g]/ and sodium arsenate 
(NagHAsO^). The solubility of arsenates is dependent on the 
cation in the same manner as described for arsenites. 
Arsenates and arsenites have a wide range of uses ranging 
from insecticides, herbicides, wood preservatives and others. 
Arsenous acid and arsenic acid esters, such as 
triorganyl arsenite [(ROi^As] and triorganyl arsenate 
[(ROjgAsO], can be prepared but are very easily hydrolyzed at 
the arsenic-oxygen-carbon bond. These esters are therefore 
very unstable in aqueous environments. 
Arsenic acid (H^AsO^) and phosphoric acid (H^PO^) are 
very similar and could possibly be interchanged in some 
important biological molecules. Due to the rapid hydrolysis 
of arsenic acid esters in aqueous media, these molecules 
would degrade prematurely and block some important metabolic 
pathways. Two biologically important molecules that may be 
susceptible to the substitution are adenosine triphosphate 
and glucose-l-phosphate (NAS, 1977). 
Hydrogen sulfide reacts with arsenic in anaerobic 
aqueous media forming arsenic sulfides which readily 
precipitate. Realgar (ASgSg), orpiment (ASgS^), and arsenic 
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pentasulfide are the most important arsenic sulfides. 
Realgar is a natural arsenic ore (NAS, 1977). Realgar and 
orpiment have been known since 400 B.C. and have been used as 
medicine, pigments, and depilatories in tanneries (Buchanan, 
1962). 
Sources of Arsenic 
There are many ways for animals or man to be exposed to 
arsenic. Woolson (1983) reviewed the literature on arsenic 
in the environment and classified the sources of exposure as 
either natural or man-made. Exposures that cause clinical 
disease are usually due to man-made sources. Natural sources 
will be discussed first. 
Natural sources 
Earth crust The twelfth most abundant element in the 
crust of the earth is arsenic. The continental crust is 1.5-
2.0 ug/gm arsenic. At least 245 different minerals contain 
arsenic. Arsenic is usually found in association with sulfur 
and found in the following forms (Woolson, 1983). 
1) native element or alloys (4 minerals) 
2) arsenides (27 minerals) 
3) sulfides (13 minerals) 
4) sulfosalts (sulfides of arsenic with metals, 65 
minerals) 
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5) oxidation products of the above (2 oxides, 11 
arsenites, 116 arsenates, and 7 silicates) 
Of the arsenic containing minerals, arsenopyrite is the most 
common. When exposed to air, arsenic-containing sulfides and 
sulfosalts are oxidized to arsenic trioxide and then to 
arsenate. Rocks vary in arsenic content, sedimentary usually 
contain more than igneous. Sedimentary iron and manganese 
ores are high in arsenic with concentrations up to 2,900 and 
15,000 ug/gm respectively. Oil shale averages around 100 
ug/gm arsenic (Woolson, 1983). It is present at about 2 
ug/gm in igneous rocks (Kipling, 1977). 
Natural levels of arsenic are sometimes difficult to 
define. For example, the surface 6 cm of fresh water 
sediments is higher in arsenic than the rest. This elevation 
is attributed to man's activity (Woolson, 1983). 
Arsenic is present in all soils with concentrations 
ranging between 0.1 to 40 ug/gm and averaging around 5 to 6 
ug/gm. The concentration of arsenic in soil varies with the 
arsenic content of the rock the soil is from. The soil over 
sulfide ore deposits have arsenic concentrations of several 
hundred ug/gm. In this soil the arsenic is present as 
sulfide minerals, most commonly arsenopyrite, or in the 
inorganic anion state (Woolson, 1983). The arsenic 
concentration of virgin soil and forest humus is 3-5 ug/gm 
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(Kipling, 1977). 
Arsenic bound to organic matter is freed into the soil 
solution by oxidation of the organic matter. Once in the 
soil solution the arsenic can be taken up by plants or fixed 
by soil cations. Plants may take up arsenic contributed to 
the soil solution by iron or aluminum arsenates. 
The amount of arsenic available for plant uptake is a 
function of the chemical and physical forms of arsenic 
compounds present. Average available arsenic in cultivated 
soils is about 10 percent of the total arsenic (Woolson, 
1983) . 
Water Arsenic is present in all water. Arsenic 
concentrations in water from different lakes, rivers, wells, 
and springs vary greatly. Most arsenic in water is from 
natural sources (Woolson, 1983). Most rivers and lakes have 
concentrations well below 0.01 mg/liter (0.01 ug/gm) but up 
to 1.0 mg/liter (1.0 ug/gm) (Fowler et al., 1979a). United 
States well water had arsenic concentrations ranging from 0.0 
to 10.0 ug/gm in studies summerized by Woolson (1983). 
Naturally high arsenic concentrations occur in water from hot 
springs, ground water in areas of thermal activity, ground 
water of areas with high arsenic content in rocks, and water 
with high dissolved salt content. High arsenic levels in 
rivers and lakes are usually due to human sources. 
A major source of human arsenic exposure is drinking 
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water. In the United States drinking water is responsible 
for an estimated daily intake of 10-12 ug of arsenic 
(Kipling, 1977). Only a few water supplies very high in 
arsenic exist. One of these is the Toconce River in Chile 
with arsenic concentrations up to 0.8 ug/gm. It originates 
in the Andes Mountians 300 kilometers above the city of 
Antofagasta. Antofagasta secured its water supply from the 
river. Chronic arsenicism caused cutaneous lesions in 30 
percent of the population. Hair arsenic residues were used 
to support the diagnosis (Borgono and Greiber, 1971). 
Forms of arsenic in natural waters are arsenate, 
arsenite, methylarsonic acid and dimethylarsenic acid. 
Methylated forms are a small percentage of the total water 
arsenic. The chemical form of arsenic in ground water is 
mostly undetermined. A sample of a few ground waters showed 
25-50% of the arsenic in the trivalent form (Fowler et al., 
1979a). Surface supplies of fresh water have trivalant to 
pentavalent arsenic ratios ranging from 6.7/1 to .002/1 in 
the studies summarized by Braman (1983) . Inorganic trivalent 
and pentavalent arsenic are more of an environmental threat 
than organic arsenicals because they more intensely interact 
with the human biochemical system (Braman, 1983). It is an 
important fact that trivalent arsenicals are more toxic than 
pentavalent arsenicals. 
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Sea water has 0.001 to 0.005 mg of arsenic per liter 
(0.001-0.005 ug/gm). Arsenate has been reported as the most 
dominant form of arsenic in sea water (Fowler et al., 1979a). 
The thermodynamic calculated ratio of trivalent to 
pentavalent arsenic in oxygenated seawater at ph 8.1 is 
0.001/1, but measured values vary from 10/1 to 0.1/1. 
Biologicial reduction is believed to contribute the 
difference between calculated and measured values. The 
arsenic content in sea water is a small fraction of that 
estimated to be carried into it (NAS, 1977). Most of the 
arsenic dissolved in the sea water is deposited in sediment 
through precipitation or adsorption on marine clays. 
It is believed that surface waters, fresh and saline, 
are self-purifying by deposition of arsenic in the sediment. 
Sediments always have a higher concentration of arsenic than 
the water with which they are associated (NAS, 1977). 
Air Arsenic concentrations in air vary from <0.02 
3 3 
ug/m in areas remote to industry to 0.16 ug/m in some urban 
areas (NAS, 1977). A quarterly average of 1.4 ug/m^ was 
recorded in El Paso, Texas near a large copper smelter 
(Fowler et al., 1979a). 
Plants Arsenic is ubiquitous in the plant kingdom. 
The concentrations in plants vary from <0.01 to 5 ug/gm on a 
dry-weight basis. The concentration of naturally occurring 
arsenic in plants depends on variation between individual 
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plants, plant species, available soil arsenic, and growing 
conditions (NAS, 1977). Natural plant arsenic accumulation 
is almost always in the pentavalent form (Kipling, 1977). 
Injury occurs to plants accumulating arsenic before plant 
arsenic concentrations are toxic to animals that may eat them 
(NAS, 1977). However, arsenical insecticide or herbicide 
surface contamination increases arsenic concentrations in 
plants to the point of causing a hazard. 
Marine plants have a high naturally accumulated arsenic 
content. British seaweed has arsenic concentrations ranging 
from 5.2 to 94 ug/gm (NAS, 1977). 
Animals Arsenic is present in all living organisms. 
Domestic animals and man usually have less than 0.3 ug/gm on 
a dry matter basis. Fresh water fish have concentrations 
usually less than 1 ug/gm and marine fish up to 10 ug/gm. 
Bottom dwelling and feeding marine organisms generally have 
high arsenic concentrations ranging up to 100 ug/gm (NAS, 
1977). 
Foodstuffs As noted above all living organisms 
contain arsenic and therefore all foodstuffs must contain 
arsenic. In the United States a specific non-seafood diet 
gives a person 0.04 mg of arsenic per day. A more average 
diet gives about 0.19 mg of arsenic per person per day. In 
Japan, the daily arsenic intake is 0.07-0.37 mg/person. 
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Japan has a higher arsenic intake probably due to increased 
consumption of food from the sea. Marine organisms contain 
about ten times as much arsenic as other food sources (Fowler 
et al., 1979a). 
Man-made sources 
This section will deal with the sources of arsenic that 
are the result of the perturbation of the natural 
distribution of arsenic by man. 
Man realized the value of arsenic compounds in very 
early times. Arsenic sulfides were known to and recommended 
by Hippocrates (460-377 B.C.) for medicinal uses (Buchanan, 
1962). The listing of arsenical compounds and their uses 
through the ages would be interesting but overwhelming. The 
following discussion will be limited to major uses in recent 
times. 
Sources from the utilization of natural resources 
Mining and processing of natural resources releases arsenic 
into air, water, and soil. A few important examples are 
discussed below. 
Most mining operations produce large amounts of tailings 
dumped in piles next to the mine or processing plants. The 
sulfur compounds in the tailings oxidize and combined with 
water to form acid. The acid solution dissolves and leaches 
away many elements including arsenic. Therefore the drainage 
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waters of these piles can be high in arsenic. The effect on 
the environment depends on the accessibility of the drainage 
water to natural surface or ground water (Piver, 1983). 
Lagoons of water for processing ore or coals can be high 
in arsenic. Contaminated soil and ground water can occur if 
a low permeability lagoon liner is not present (Piver, 1983). 
Smelters can be major point sources of arsenic. Arsenic 
trioxide is abundant in crude flue dust from lead, copper, 
and gold smelters. Collecting and roasting this dust is how 
most commercial arsenic is obtained. Efforts are made, with 
variable success, to prevent the emission of the flue dust 
into the environment. Despite these efforts a portion of the 
arsenic trioxide is emitted as particulates into the air 
(Piver, 1983). 
A well documented point source of arsenic is the copper 
smelter in Tacoma, Washington. The Puget Sound Air Pollution 
Control Agency estimates the yearly arsenic trioxide emission 
into the air was 1,176 tons in 1971 decreasing to 400 tons in 
3 1980 (Piver, 1983). Air concentrations were 0.5 to 2.5 ug/m 
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at the property line and 0.02 to 0.13 ug/m eight miles from 
the smelter. Settling and rainfall increased the soil 
arsenic concentrations in the area. Soil concentrations were 
380 ug/gm near the smelter, and 100-300 ug/gm on islands four 
kilometers to the north by north east. Arsenic 
concentrations in dust from houses in the vicinity were 77 to 
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4,461 ug/gm (Woolson, 1983). Background soil concentrations 
must be considered when interpreting these figures because 
smelters are probably located in arsenic rich areas. 
Fossil fuel combustion releases arsenic into the air. 
Eastern, mid-western, and western United States coal contains 
an estimated 10, 5, and 1 ug/gm of arsenic respectively. 
Most of the arsenic is trapped in the dust collecting 
equipment of coal burning plants. 
An estimated eight hundred forty tons of arsenic was 
collectively emitted from coal burning plants in 1973 
(Woolson, 1983). Therefore coal burning does not have as 
much effect on local environmental arsenic concentrations as 
a smelter does. 
The average arsenic concentration of oil is 0.042 ug/gm. 
Arsenic concentrations in emissions from oil burning plants 
should not cause an environmental problem. Shale oil on the 
other hand could cause a problem. Oil from Colorado shale 
has an arsenic concentration of 82 ug/gm (Woolson, 1983). 
Manufactured sources United States consumption of 
arsenic has been going down since the sixties and early 
seventies. However the consumption of arsenic trioxide, the 
raw material of most arsenicals, in the late seventies was 
still about twenty thousand short tons (Fitzgerald, 1983). 
The American Smelting and Refining Company estimated the 1981 
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United States arsenic market to be as follows. 
Wood Preservatives 
Herbicides 
Cotton Desiccants 
Moly Flotation 
Glass Production 
Miscellaneous 
36% 
31% 
15% 
8% 
5% 
5% 
Following is a list of a few common arsenicals and their 
uses. 
Arsenic acid 
Chromated copper arsenate 
Arsenic trioxide 
Calcium arsenate 
Lead arsenate 
Sodium arsenate 
Sodium arsenite 
Methane arsonic acid & salts 
Cacodylic acid & sodium salts 
Arsanilic acid 
3-nitro-4-
hydroxyphenylarsonic acid 
Desiccant (cotton) 
Wood preservative 
Wood preservative 
Rodenticide 
Pesticide 
Grapefruit growth 
regulator 
Ant killer 
Herbicide 
Herbicide 
Defoliator (cotton) 
Feed additive 
Feed additive 
Exposure to these chemicals can occur during their 
production, distribution, or application. Their application 
can produce residues in the air, soil, water, plants, or 
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animals which are also sources of exposure. 
Repeated high level use of arsenical pesticides raises 
the arsenic content of soil significantly. Woolson (1983) 
summarized a number of studies on the effect of repeated use 
of lead arsenate, calcium arsenate or sodium arsenite on soil 
residues. Most residues were in the area of 100 to 200 ug/gm 
compared to background levels from 5 to 15 ug/gm. 
In orchards where inorganic arsenical pesticides were 
used at high levels for prolonged periods the soil becomes 
phytotoxic. Plant growth is limited in soils high in 
arsenic; therefore significant human exposure to arsenic by 
comsumption of plants grown in these soils is minimal (NAS, 
1977) . 
Woolson (1983) also reviewed literature on various 
arsenical pesticides experimentally applied. He concluded 
that if the chemicals were used at currently recommended 
levels there was minimal accumulation. 
The use of chromated copper arsenate and ammoniacal 
copper arsenate as wood preservatives is increasing greatly. 
One hundred fifty million cubic feet of wood was treated with 
these products in 1979, versus fifteen million cubic feet in 
1969 (Baldwin, 1983). Wood treated this way only minimally 
contaminates soil with which it is in contact (NAS, 1977). 
Feed additive arsenicals do not greatly increase arsenic 
levels in animal products over background levels. In fact 
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most normal marine animal arsenic levels are higher than 
those of domestic animals treated with arsenical feed 
additives (NAS, 1977). 
Inorganic Arsenic as a Toxicant 
History 
I am an evil, poisonous smoke... 
But when from poison I am freed, 
Through art and sleight of hand 
Then can I cure both man and beast, 
From dire disease ofttimes direct them; 
But prepare me correctly, and take great care 
That you faithfully keep watchful guard over me; 
For else I am poison, and poison remain. 
That pierces the heart of many a one. 
Valentini, 1694 (NAS, 1977) 
This poem exposes the double edged nature of arsenic. 
By 2000 B.C. arsenic trioxide, produced as a byproduct of 
copper smelting, was used as a medicine and a poison 
(Pershagen, 1983) . 
Professional poisoners used arsenic extensively in the 
Middle Ages. In the nineteenth century one third of the 
criminal poisonings in France were blamed on arsenic 
(Pershagen, 1983). 
In the 1700s and 1800s Fowler's solution, a one percent 
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solution of arsenic trioxide, was used extensively for 
diseases such as psoriasis and bronchial asthma. The mild 
toxic side effects of gasterointestinal discomfort and pain 
were ignored. If the oral dose could not be tolerated, per 
rectum administration was used. If, the treatment caused 
severe signs of vomiting and diarrhea the dose was lowered 
(Pershagen, 1983). 
Occupational toxic exposures increased with the 
increased industrial use of arsenic over the last 100 years. 
Well documented mass human poisonings have occurred 
through contamination of food and drink with arsenic. The 
Manchester (England) beer incident in 1900, the Morinaga 
(Japan) milk incident of 1955 and the soy sauce incident of 
1956 in Japan are well documented cases (Pershagen, 1983). 
The accidental contamination of the environment from the 
utilization of natural resources and the continued 
industrial, agricultural and domestic use of arsenic make the 
possibility of poisoning real. 
Metabolism 
Absorption Studies in mice, dogs, and monkeys have 
shown that aqueous solutions of inorganic arsenicals are 
almost completely absorbed from the gastrointestinal tract 
(Charbonneau et al., 1978a; Hollins et al., 1979; Vahter and 
Norin, 1980). Mice absorb trivalent and pentavalent 
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inorganic arsenic solutions at the same rate. The absorption 
was not dose dependent within the range 0.4 to 4.0 mg/kg of 
bodyweight (Vahter and Norin, 1980). 
If a toxicant is relatively insoluble it will have 
limited contact with the gastrointestinal mucosa and will not 
be extensively absorbed. Limited gastrointestial absorption 
occurs if a powdered arsenical particle size is too large 
(Klaassen, 1980). Lack of absorption is why insoluble 
arsenical compounds or arsenicals consisting of coarse 
particles are less toxic than highly soluble arsenicals 
(Schwartze, 1922; Done and Peart, 1971). 
Topically applied inorganic arsenicals not only cause 
local skin damage but are absorbed causing systemic poisoning 
(Buchanan, 1962; Evinger and Blakemore, 1984). 
Respiratory absorption depends on the chemical form of 
the inorganic arsenic inhaled (Pershagen, 1980). Water 
soluble sodium arsenate is rapidly absorbed from the lungs of 
rats (Dutkiewicz, 1977). 
Tissue distribution 
Blood After absorption, arsenic is transported 
in the blood to all organs of the body. Clearance of arsenic 
from the blood of humans, dogs, mice, and rabbits follows a 
two or three phase exponential curve (Ducoff et al., 1948; 
Charbonneau et al., 1978b; Vahter and Norin, 1980; Bertolero 
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et al, 1981). The first phase is the largest (>90%). It is 
eliminated rapidly with a half-time of one to two hours. The 
second and third phases have estimated half-times of 30 and 
200 hours respectively. 
Rats are significantly different than the above 
mentioned species. Shortly after dosing they have high blood 
arsenic concentrations that remain high (Ducoff et al., 
1948). Blood half-times are over 60 days (Lanz et al., 
1950). This is due to arsenic binding to the eyrthrocytes. 
Blood arsenic concentration is 10 to 100 times higher than 
most other tissues (Klaassen, 1974) 
Arsenic in rabbit and rat erythrocyte cytosol is 
associated with high molecular weight proteins (Marafante et 
al., 1982). Arsenic binds to erythrocyes longer and in 
higher concentrations in rats than rabbits. The 
concentration of arsenic in the red blood cells relative to 
the plasma varies with the valence of the arsenical. The 
trivalent inorganic arsenicals bind erythrocyte cytosol more 
readily than the pentavalent inorganic arsenicals (Vahter and 
Norin, 1980). 
In rabbit studies, inorganic arsenic is poorly bound to 
plasma proteins (Bertolero et al., 1981; Marafante et al., 
1981). After administration of trivalent or pentavalent 
inorganic arsenic the forms found in the blood are: 
trivalent and pentavalent inorganic arsenic, dimethylarsinic 
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acid (DMA), and methylarsonic acid ( MMA). 
Other tissues The main organs of accumulation 
of inorganic arsenic in rabbits and mice are liver, kidney, 
and intestinal mucosa (Deak et al., 1976; Vahter and Norin, 
1980). Human distribution is similar (Ducoff et al., 1948). 
Parenteral administration results in rapid high intestinal 
mucosal arsenic concentration (Deak et al., 1976; Lindgren et 
al., 1982). Vahter (1983) believes the accumulation is 
caused by blood transport versus bile excretion due to its 
rapid occurrence. 
Fibroblasts in cell culture accumulate greater 
concentrations of trivalent arsenic than pentavalent (Fischer 
et al., 1985). Mice given a dose of 4 mg/kg accumulate 
higher tissue arsenic concentrations if the arsenic given is 
in the form of arsenite versus arsenate (Vahter and Norin, 
1980). This is also true in rabbits (Vahter and Marafante, 
1983). At lower doses this difference is not as large. The 
difference is more apparent if the route of administration is 
intra-venous versus oral. The bone is different than most 
tissues having higher affinity for arsenate than arsenite 
(Deak et al., 1976; Lindgren et al., 1982). 
When low doses of arsenate or arsenite are given, 
parentally or especially orally, the differences in tissue 
arsenic concentrations are small or insignificant (Sabbioni 
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et al., 1979; Vahter and Norin, 1980). A likely explanation 
is that at low concentrations the body can readily methylate 
both arsenate and arsenite completely to dimethylarsinic acid 
therefore negating any difference in valence. At high doses 
the body is overwhelmed and a large percentage of the dose 
remains in the trivalent or pentavalent form and tissue 
concentration differences occur. Affinity of trivalent 
arsenic for protein sulfhydryl groups is thought to cause the 
observed high tissue concentrations. 
Placental transfer of arsenic has been shown in 
hamsters, mice, and monkeys (Hanlon and Ferm, 1977; Lindgren 
et al., 1982). 
Two to three days after a one time exposure to inorganic 
arsenic, concentration of arsenic in most organs falls off 
rapidly, the exception being erythrocytes in rats. 
The lens of the eye, hair, and nails are the last organs 
to give up their arsenic (Vahter, 1983). 
When experimental animals are exposed to arsenic in 
drinking water or by inhalation, tissue concentrations 
increase for 2 weeks and then decrease despite continued 
arsenic exposure (Vahter, 1983). Possible explanations are 
increased excretion capacity, or decreased absorption. 
Increased methylation of arsenic would increase its urinary 
excretion rate. Another possible explanation has been worked 
out in rats. Orally administered arsenite binds to 
25 
glutathione in the intestinal mucosa of rats and increases 
mucosal cell synthesis of glutathione to twice normal 
concentrations (Pisciotto and Graziano, 1980). This prevents 
the systemic distribution of the arsenic. 
Biotransformation of inorganic arsenic Two to 3 days 
after exposure to inorganic arsenic humans, mice, rabbits, 
and dogs excrete 46, 83, 83,and >95 percent of the 
administered arsenic in the urine respectively (Buchet et 
al., 1981; Marafante et al., 1981; Tsukamoto et al., 1983b; 
and Vahter et al., 1984). Urinary arsenic is present as 
inorganic arsenic, MMA, or DMA. Mice and rabbits differ from 
humans in that they excrete very little MMA. Humans excrete 
20 to 30 percent of a total dose of arsenic as MMA in the 
urine (Vahter, 1983). In fibroblast cell cultures both 
trivalent and pentavalent inorganic arsenic are converted 
intracellularly to MMA and DMA and released into the culture 
medium (Fischer et al., 1985). Cell uptake and methylation 
of trivalent arsenicals is greater than that of pentavalent 
arsenicals. 
When trivalent inorganic asenic, rather than 
pentavalent, is given to a rabbit or mouse, an increased 
percentage of the excreted urine arsenic is in the DMA form 
and less in the inorganic form (Vahter, 1983). Over 50 
percent of the total arsenic in ultrafiltrable fractions of 
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liver and kidney of rabbits exposed to 0.001 mg/kg of 
arsenite is in the DMA form (Bertolero et al., 1981). 
Recent studies suggest the liver as the major site of 
arsenic methylation (Buchet and Lauwerys, 1985; Marafante et 
al., 1985). Homogenates of rat eyrthrocytes, brain, lung, 
intestine, and kidney had insignificant inorganic arsenic 
methylating capacity compared to the liver. The proposed 
detoxification of inorganic arsenic goes as follows; the 
pentavalent form is reduced to the trivalent form, then a 
methyl group is added to form MMA and a second methyl group 
added to MMA to form DMA. 
Mice and rabbits given pentavalent arsenate have 
trivalent arsenic in their plasma and urine after one hour 
(Vahter and Envall, 1983). 
DMA injected into mice and rabbits is essentially 
completely excreted in the urine within 24 hours (Vahter and 
Envall, 1983). This is evidence that DMA production is an 
important step in the elimination of arsenic from the body. 
In vitro arsenic methylation in rat liver occurs in the 
cytosol and accepts only trivalent arsenic as a substrate. 
Glutathione is required and s-adenosylmethionine is the 
essential methyl donor (Buchet and Lauwerys, 1985). 
Dose level affects vivo methylation of arsenic. The 
percent of the total urine arsenic in the form DMA goes down 
as the dose goes up (Vahter, 1983). 
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In mice a higher degree of methylation occurs if arsenic 
is given in the form of arsenite rather than arsenate 
(Vahter, 1981). Subcutaneous administration of arsenite to 
mice gives less methylated urinary arsenic and higher tissue 
retention rates than oral administration (Vahter, 1981). 
Pretreatment of fibroblast cell cultures with low doses of 
trivalent arsenic caused increased biotransformation of 
inorganic arsenic to MMA and DMA (Fischer et al., 1985). 
This made the fibroblasts less sensitive to toxic doses of 
trivalent or pentavalent inorganic arsenic. 
Elimination 
Fecal elimination Usually little arsenic is 
eliminated via the feces when a soluble inorganic arsenical 
is orally administered. That is if the preparation is a 
solution or a powder of fine particle size. 
Biliary excretion is highly significant in some species. 
Rats excrete arsenic in the bile 40 times faster than rabbits 
and 800 times faster than dogs (Klaassen, 1974). Biliary 
excretion is higher if the arsenical is in the trivalent 
versus the pentavalent form (Vahter and Norin, 1980). 
Enterohepatic circulation causes little biliary arsenic to be 
eliminated in the feces, even when the biliary excretion is 
large (Klaassen, 1974). 
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Urinary elimination In most species 40 to 70 
percent of an absorbed dose of inorganic arsenic is excreted 
in the urine within 48 hours (Vahter, 1983). The rat is a 
major exception to this rule. 
Urinary excretion rates of arsenic are affected by 
valence, methylation, dose, route of administration, and 
animal species (Vahter, 1983). Trivalent arsenic is excreted 
slower from mice than pentavalent arsenic even though 
trivalent arsenic is largely methylated. This is due to the 
binding of trivalent arsenic to tissues and the excretion of 
pentavalent arsenic into the urine without methylation 
(Vahter, 1981; Vahter and Envall, 1983; Vahter and Marafante, 
1983) . 
The more efficient the methylation process the more 
efficient the urinary excretion. In vivo inhibition of 
methyltransferase activity causes decreased urinary excretion 
and increased tissue concentrations of arsenic after the 
administration of arsenate or arsenite (Marafante and Vahter, 
1984; Marafante et al., 1985). Methylation and urinary 
excretion are decreased by parenteral administration and an 
increased dose of arsenic (Vahter, 1981). Species difference 
in urinary excretion may be due to different abilities to 
methylate arsenic (Vahter, 1983). 
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Other routes of elimination Sweat, hair, milk, 
skin desquamation, and exhalation are arsenic elimination 
routes of low significance relative to urinary excretion. 
Biological half-time A three-exponential function 
best fits the whole body elimination of inoganic arsenic in 
man and dog (Hollins et al., 1979; Pomroy et al., 1980). The 
half-times of the first two compartments are significantly 
smaller in the dog. This is probably due to more efficient 
methylation of arsenic in dog than man. 
Factors effecting toxicity 
Purity The greater the purity of an inorganic 
arsenic preparation the greater its toxicity. Harrisson et 
al. (1958) showed this to be true in mice and rats orally 
exposed to solutions and dry preparations of arsenic 
trioxide. This means if 99 and 95 percent pure preparations 
were given to an animal on an equal arsenic basis, the 99 
percent preparation would be the most toxic even when the 
total arsenic given was the same. Crude preparations of 
arsenic trioxide were greater gastrointestinal irritants but 
less lethal than preparations of greater purity. 
Solubility Solutions of inorganic arsenicals are 
much more toxic than powders of the same compound (Harrisson 
et al., 1958). As a general rule the more soluble the 
arsenical compound the greater its toxicity (Done and Peart, 
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1971). 
Particle size The smaller the particle size of a dry 
inorganic arsenical, given orally, the greater its toxic 
effect (Schwartze, 1922). 
Valence Trivalent arsenicals are 4 to 10 times more 
toxic than pentavalent arsenicals. This has been shown to be 
true in in vivo and vitro (tissue culture) studies (Franke 
and Moxon, 1936; Savchuck et al., 1960). 
Trivalent arsenicals interact with sulfhydryl groups of 
compounds in biological systems. In many cases this alters 
the activity of vital compounds and causes toxicosis. Most 
documentation is on inactivation of enzymes but coenzymes and 
substrates could also be effected (Squibb and Fowler, 1983). 
Long lists of enzymes susceptable to trivalent arsenic have 
been compiled (Webb, 1966; Squibb and Fowler, 1983). 
Pentavalent arsenicals are reduced to more toxic 
trivalent forms vivo. But pentavalent arsenic ion 
(arsenate) can also cause direct toxic effects. Squibb and 
Fowler (1983) have summarized the literature which shows that 
arsenate ion is isosteric and isoelectric with phosphate ion. 
Therefore, arsenate can substitute for phosphate in many 
important metabolic reactions. The arsenate esters formed 
undergo instantaneous spontaneous hydrolysis termed 
"arsenolysis". This causes interruption of metabolic 
pathways by spontaneous breakdown of critical intermediates 
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such as glucose-6-arsenate. Also cell energy stores can be 
depleted by the production of ADP-arsenate, instead of ATP, 
that spontaneously hydrolyzes producing no work (Moore et 
al., 1983; Squibb and Fowler, 1983). 
Species Susceptibility to inorganic arsenic varies 
between species as follows; man> dog> rat> mouse (Harrisson 
et al., 1958; Hayes, 1982). Dangerous consequences can 
result from extrapolating toxicity data from rat and mouse 
studies for use in human situations. 
Much of the experimental data on arsenicals is based on 
rat studies. It is generally accepted now that the rat is a 
poor animal model due to its unique metabolism of arsenic. A 
summary of the literature by M. Vahter (1983) shows that the 
blood half-life in the rat is months verses hours for humans, 
dogs, mice, and rabbits. This is due to binding of arsenic 
to rat erythrocytes. The binding of arsenic to erythrocytes 
causes rats to excrete arsenic very slowly into the urine and 
feces. The arsenic is rapidly excreted into the bile for the 
first six minutes after dosing. Then bile excretion rapidly 
decreases due to the redistribution of the arsenic from the 
liver to the blood. However, less than 10 percent of the 
total dose is excreted into the feces in the first seven days 
due to enterohepatic circulation. Only 20 percent of the 
total dose is excreted by the urine and feces in seven days 
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(Klaassen, 1974). 
Condition of the animal Weak, debilitated, and 
dehydrated animals are more susceptible to arsenic toxicosis 
than normal healthy animals (Osweiler et al., 1985). 
Toxicosis 
Inorganic and trivalent aliphatic arsenicale cause 
similar toxicoses (NAS, 1977). Phenylarsonic acid (aromatic) 
compounds cause different clinical signs than inorganic 
arsenicals. These aromatic arsenicals cause incoordination 
and paralysis due to peripheral neuropathy (NAS, 1977). 
Discussion of inorganic arsenical poisoning will be divided 
into two parts, acute to subacute and subchronic to chronic. 
Descriptions that follow are of toxicoses produced by oral 
exposure unless otherwise noted. In general, signs and 
lesions are similar when arsenic is administered orally or 
parenterally. 
Acute to subacute toxicosis Experimental studies 
verify descriptions of spontaneous poisonings. Peracute and 
acute oral poisonings have dramatic signs with high morbidity 
and mortality. Signs may occur within minutes if a high dose 
of dissolved arsenic is ingested. Death may occur in hours. 
Progression of signs is as follows: intense abdominal pain, 
salivation, vomiting, staggering gait and weakness, 
diarrhea, rapid weak pulse, prostration, subnormal 
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temperature, collapse, and death (NAS, 1977; Osweiler et al., 
1985) 
The course of subacute oral poisoning is basically the 
same as acute but slightly prolonged. Death occurs in 
several days. This is long enough for anorexia and oliguria 
to develop and be assessed. The urine contains protein, red 
blood cells, and casts (NAS, 1977; Osweiler et al., 1985). 
Peracute poisoning causes death so rapidly no gross or 
microscopic lesions may be present. Gross lesions of acute 
and subacute poisoning consist of multifocal to diffuse 
reddening of the mucosa of the stomach and proximal small 
intestine, variable amounts of watery fluid in the 
gastrointestinal tract, a soft yellow liver, and wet red 
lungs. If the animal lives longer then edema, hemorrhage, 
and necrosis of the gastrointestinal tract cause blood and 
shreds of mucosa to be present in the stool. Perforation of 
the stomach or intestine may occur. There is splanchnic 
organ congestion with petechial hemorrhage of serous 
membranes. Hemorrhages are especially prominent in the heart 
(NAS, 1977; Sullivan, 1985). Gastrointestinal lesions are 
the most consistent and prominent of those listed. The 
others may not be present. 
Histological lesions consist of: gastrointestinal 
mucosal and submucosal congestion, edema, and variable 
hemorrhage; gastrointestinal mucosal epithelial necrosis and 
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sloughing; mild fatty degeneration to necrosis of liver; 
renal tubular degeneration; and if the animal lives three to 
four days, cerebral edema and petechiation (NAS, 1977; 
Osweiler et al., 1985; Sullivan, 1985). 
Harrisson et al. (1958) showed, that in mice and rats 
solutions of crude arsenic trioxide caused marked 
gastrointestinal hemorrhage whereas solutions of pure arsenic 
trioxide only caused slight reddening. Percentages of purity 
of the two preparations were 97.7 and 99.9 respectively. The 
impurities may in themselves be gastrointestinal irritants. 
Frank liver necrosis is not common but has been reported 
in rabbits exposed to inorganic arsenicals and dogs exposed 
to arsphenamine (an aromatic organic arsenical) (Soffer et 
al., 1937; Von Glahn et al., 1938). 
Renal tubular degeneration is reported by many authors 
as a common lesion produced by inorganic arsenicals. 
Tsukamoto et al. (1983a) reported renal tubular degeneration 
and necrosis in dogs exposed to intravenous sodium arsenate. 
If the poisoning occurs by skin contact, many of the 
same systemic signs described above occur. However, in this 
case skin lesions are prominent with blistering, edema, 
cracking, bleeding, and secondary infection (NAS, 1977; 
Evinger and Blakemore, 1984). 
Inorganic arsenic is often considered a "capillary 
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poison". The acute toxic effects are attributed to a direct 
action on capillaries. This conclusion is supported by the 
observed congestion, edema, and hemorrhage present in 
visceral organs of acute poisonings. Webb (1966) reviewed 
the literature and found considerable contradiction on the 
effect of arsenicals on capillaries. He recommended that 
more thorough and critical work be done before definite 
statements could be made. Review of recent literature does 
not provide experimental verification that arsenic is a 
capillary poison. It is clear splanchnic capillary networks 
are affected by arsenic (Hanna nd McHugo, 1960). But whether 
this is a direct or indirect effect of arsenic is far from 
clear. 
Subchronic to chronic toxicosis There is little 
documentation of spontaneous chronic arsenic poisoning in 
animals. However, the human medical literature is filled 
with descriptions of human populations chronically exposed to 
arsenic. The descriptions vary considerably and may even 
conflict, reflecting the variation in exposure scenarios. 
Pershagen reviewed numerous epidemiologic studies of chronic 
human exposure to arsenic. Major changes cited were; 
hyperpigmentation, palmoplantar hyperkeratosis, basal cell 
carcinoma, and squamous cell carcinoma of the skin; 
rhinopharyngolaryngitis; nasal septum perforation; 
bronchitis; emphysema; lung cancer; portal hypertension. 
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cirrhosis, and angiosarcoma in the liver; cardiovascular 
disease; anemia; granulocytopenia; lymphocyte chromosome 
abnormalities; neoplasia of the hematopoietic and lymphatic 
systems; peripheral neuropathy; encephalopathy; congenital 
defects; spontaneous abortion (Pershagen, 1983). 
Numerous controlled experiments have been done on the 
effects of subchronic and chronic exposure to inorganic 
arsenic. Following is a summary of some of these effects. 
Weight gain and feed consumption are adversely affected 
in a dose dependent manner. Weanling piglets had reduced 
weight gain and feed consumption when fed feed containing 100 
ppm of sodium arsenite and 0.175 ppm selenium (Morrison and 
Chavez, 1983). The effect was negated if the arsenite 
contaminated feed was deficient in selenium (0.075 ppm) 
therefore suggesting that selenium enhances the toxic effect 
of arsenic. This contradicts the widely held belief that 
arsenic and selenium are antagonistic. 
Mice were exposed for six weeks to drinking water 
containing 0.0, 20, 40, and 85 ppm of arsenic as sodium 
arsenate. The 40 and 85 ppm groups had a significant 
depression of weight gain and water consumption (Fowler and 
Woods, 1979). 
Growth rates of mice and rats given 5.0 ppm of sodium 
arsenite in the water were not affected. The exposure lasted 
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from weaning to natural death. Life-spans of the exposed 
mice, but not rats, were somewhat shortened (Schroeder and 
Balassa, 1967; Schroeder et al., 1968). Rats exposed for 6 
weeks to 215 ppm of arsenic as arsenic trioxide in the feed 
showed no adverse effects (Finner and Calvery, 1933). An 
aqueous solution of 5.0 to 10.0 mg of arsenic trioxide was 
given orally to infant rats on day 1 to day 21 of life. 
Exposed rats had a dose dependent decrease in weight gains 
(Kiyono et al., 1974). Rats exposed to 85 ppm arsenic as 
sodium arsenate in the drinking water had a significant 
depression of growth rate (Fowler et al., 1977). 
In another study, rats were given feed contaminated with 
250, 125, 62.5, 31.25, 15.63, or 0 ppm of sodium arsenite or 
400, 250, 125, 62.5, 31.25, or 0 ppm of sodium arsenate. 
Both compounds caused a dose dependent depression of body 
weights. Weights of the lower dose groups were not affected. 
Survival rates were decreased in the high dose group fed 
sodium arsenite and in the two highest dose groups fed sodium 
arsenate (Byron et al., 1967). 
Dogs chronically fed 0.5 or 2.0 mg of arsenic per Kg of 
body weight daily had no adverse effects. The arsenic was in 
the form of finely powdered arsenic trioxide. Daily feed 
consumption and weekly body weight were among the parameters 
measured (Calvery et al., 1938). 
In a large two year study, 10 groups of six dogs each 
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were fed either sodium arsenite or sodium arsenate at arsenic 
levels of 125, 50, 25, 5, or 0 ppm. Five of six dogs in the 
125 ppm sodium arsenite group were found dead or moribund 
within nine months. The last dog in that group died at 19 
months into the experiment. These dogs lost 44 to 61 percent 
of their initial body weight. A dog on 5 ppm of sodium 
arsenite and one control dog also had severe weight loss. 
Emaciation was the only consistent post-mortem finding of the 
above mentioned dogs. Weight loss was significant in the 125 
ppm sodium arsenate group but only one of these dogs died 
before the end of the test. High dose groups on both 
compounds developed mild anemia (Byron et al., 1967). 
Inorganic arsenic is accumulated in the livers of 
exposed animals. Arsenic has been associated with liver 
damage throughout history and has been the subject of many 
studies. 
Sixteen rabbits weighing between 1,250 and 1,500 grams 
were fed oats and hay daily contaminated by 1.5 mg of arsenic 
as sodium arsenate. Rabbits were periodically terminated 
from day 3 to day 231. Histopathology of the livers showed 
early hepatocyte necrosis which was most extensive in the 
portal areas. In time the necrosis was replaced by fibrosis, 
causing marked widening of the portal areas. Bile duct 
proliferation was present in many animals but not always. 
All exposed animals had some fibrotic changes except the one 
39 
terminated on day three, which had necrotic changes (Von 
Glahn et al., 1938). 
Rats consuming 500 gm of feed containing 215 ppm of 
arsenic as arsenic trioxide had no gross or microscopic liver 
changes. Six weeks was the average, time needed for each rat 
to consume 500 mg of feed (Finner and Calvery, 1939). 
Another author reported mild hepatocyte swelling in rats 
given feed containing 50 ppm of arsenic as sodium arsenate 
for 10 weeks (Mahaffey et al., 1981). The later study showed 
a significant unexplained decrease of serum alkaline 
phosphatase and serum glutamate-oxalate transaminase. 
More than 80 percent of rats fed inorganic arsenic for 
two years had common bile duct enlargement. Feed contained 
250 ppm of arsenic as sodium arsenite or 400 ppm of arsenic 
as sodium arsenate. Incidence of the lesion decreased as the 
arsenic concentration decreased. Other treatment changes 
reported from this study included "some" proliferation of 
small intrahepatic bile ducts in the high dose groups of 
either compound and variation of hepatocyte size in high dose 
sodium arsenite groups (Byron et al., 1967). 
Hepatoctye mitochondria of rats exposed to sodium 
arsenate for six weeks in the drinking water underwent 
morphological and functional change. Significant increases 
occured in the mitochondrial volume density and surface 
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density of the inner mitochondrial membrane. Increased in 
vivo incorporation of ^^C-leucine into mitochondrial proteins 
were present in arsenic treated rats. Cytochrome C oxidase 
and monoamine oxidase are inner and outer mitochondrial 
membrane enzymes respectively. Activities of both of these 
enzymes were increased. The activity of malate 
dehydrogenase, a mitochondrial matrix enzyme, was not 
affected. Mitochondria, using pyruvate-malate as a 
substrate, had decreased state 3 respiration and a decreased 
ratio between state 3 and state 4 respiration. The 
mitochondrial NAD/NADH ratio was double. Respiration with 
succinate as the substrate was not affected except at high 
doses of sodium arsenate (Fowler et al., 1977; Fowler et al., 
1979b). Mice given sodium arsenate at this same rate did not 
have significant mitochondrial morphological changes. The 
biochemical functional changes were not present or were 
present only to a lesser extent (Fowler and Woods, 1979). 
In a two year study ten groups of six month old beagles 
were fed 0.0, 5.0, 25, 50, 125 ppm arsenic as sodium arsenite 
or sodium arsenate. All of the high dose group dogs for both 
compounds had iron-positive brown granular pigment in liver 
macrophages. The incidence of the pigment was low in lower 
dose groups. Otherwise, all the livers were grossly and 
microscopically unremarkable (Byron et al., 1967). 
Urine is the major route of excretion of inorganic 
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arsenicals. This causes the kidney to be exposed to large 
amounts of arsenic in exposed animals. Acute parenteral 
administration of sodium arsenate in dogs or p-
nitrophenylarsonic acid in rats produces renal tubular damage 
(Price, 1979; Tsukamoto et al., 1983a). 
Renal changes are not dramatic in animals chronically 
exposed to inorganic arsenic. No or only subtle light 
microscopic renal lesions were reported in numerous studies 
of rats chronically exposed to inorganic arsenic in the feed 
or drinking water (Finner and Calvery, 1939; Byron et al., 
1967; Schroeder et al., 1968) 
Rats were exposed to drinking water containing 40, 85, 
or 125 ppm arsenic as soduim arsenate for six weeks. Renal 
cortical mitochondria of the 85 and 125 ppm groups had 
decreased state three respiration and respiratory control 
ratios (state three respiration/state four respiration). All 
treated groups had swollen mitochondria and increased numbers 
of autophagolysosomes in renal proximal tubule cells (Brown 
et al., 1976). Rats in another study were given feed 
containing 50 ppm arsenic as sodium arsenate for ten weeks. 
These rats also had moderate mitochondrial swelling in renal 
proximal tubule cells. A four fold increase of renal copper 
concentration was present in exposed rats. The author raises 
the question of the role copper may have in mitochondrial 
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alterations (Mahaffey et al., 1981). 
Dogs were given feed containing 5 to 125 ppm of arsenic 
as sodium arsenite or sodium arsenate. After two years of 
exposure there were no gross or light microscopic renal 
lesions (Byron et al., 1967). 
Anemia has been reported in cases of arsenic 
intoxication in man (Pershagen, 1983). Dogs chronically 
exposed to 125 ppm of sodium arsenate or sodium arsenite in 
the feed were mildly anemic. However, these dogs were 
emaciated which could account for the anemia (Byron et al., 
1967). Erythroid maturation inhibition was produced in mice 
by intraveneous injection of sodium arsenite or sodium 
arsenate (Morse et al., 1980). This suggests a direct effect 
of arsenic on the erythron. 
Squibb and Fowler (1983) reviewed a number of studies on 
the effect of inorganic arsenic on the immune system. They 
found arsenic could enhance or inhibit immunity depending on 
the dose of arsenic and immune component measured. 
Mice were more susceptible to a viral pathogen when they 
were exposed to arsenic. Follow up studies showed arsenic 
inhibited induction and function of interferon in cell 
cultures. However, low doses of arsenic in mouse embryo 
cells increased the anti-viral action of interferon. 
Enhancement of cell-mediated tumor immunity was produced in 
mice exposed chronically to 100 ppm arsenic in the drinking 
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water. Humoral immunity of mice is suppressed by exposure to 
0.5 to 10 ppm of arsenite in the drinking water. The 
suppression is present even at very low exposure levels 
(Squibb and Fowler, 1983). 
A review by Willhite and Perm (1984) states that 
prenatal death or malformations of the axial skeleton, 
neurocranium, viscerocranium, eyes, and genitourinary system 
are caused by arsenic. Sodium arsenite is more teratogenic 
than sodium arsenate, and arsenate more than methylarsonic 
acid or dimethylarsinic acid. Methylarsonic acid and 
dimethylarsinic acid must be given in very high doses to be 
teratogenic. Other organic arsenicals are also weakly or not 
teratogenic. Stage of gestation when exposed to arsenic is 
important. Sodium arsenite at five mg/kg of body weight 
given intraperitoneally on day nine or ten of gestation in 
hamsters causes resorption of all embryos. The same dose 
given day 11 or 12 results in decrease of fetal body weight 
but no gross abnormalities. 
Squibb and Fowler (1983) have reviewed the literature on 
the carcinogenic effect of arsenic. Epidemiological studies 
suggest arsenic exposure increases the incidence of many 
types of cancer in humans. This association is not supported 
by experimental studies. In some studies arsenic appears to 
cause cancer and in others prevent it. The role of arsenic 
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as a cancer causing agent or enhancer of known carcinogens is 
yet to be defined. 
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ABSTRACT 
Thirty female beagle dogs, 7 to 8 months old, were 
assigned to 5 groups. Control, low dosage, medium dosage, 
high dosage, and pair fed groups were offered 0, 1, 2, 4, and 
0 mg of sodium arsenite per kg of body weight per day 
(mg/kg/day) respectively in their feed. On day 59 the dosage 
was doubled for the rest of the experiment which ended on day 
183. Feed consumption was measured daily and the body weight 
weekly. The pair fed group was offered the amount of feed 
that the high dosage group consumed. High dosage and pair 
fed groups were terminated in week 17 when the high dosage 
group had lost a cumulative average of 20 percent of their 
original body weight. Nominal dosages of 4 and 8 mg/kg/day 
caused significant decrease in feed consumption. Initial 
decreased feed consumption was followed by increased intake 
over time. Dogs offered 8 mg/kg/day did not fully compensate 
the lost feed intake. Nominal dosages of 4 and 8 mg/kg/day 
caused a significant decrease in body weight. The linear 
regression of pair fed group body weight over time was not 
significantly different than that of high dosage group. This 
study shows that dietary sodium arsenite causes a dose 
dependent decrease of feed consumption and body weight. 
Weight loss is caused by decreased feed consumption not by 
direct effect of the sodium arsenite. 
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INTRODUCTION 
Arsenic is ubiquitous and present in rock, soil, water, 
and living organisms. Therefore it is impossible for man or 
animals to avoid exposure. In addition to natural sources, 
the frequent use of arsenicale as herbicides and insecticidal 
baits creates the potential for accidental exposure to higher 
concentrations of arsenic. Past experimentation in dogs 
lacks detailed evaluation of the concentration at which 
dietary arsenic causes effects and what the effects are 
(Calvery et al., 1938; Byron et al., 1967). 
High dosage of arsenic results in dramatic acute 
clinical signs and lesions (Sullivan and Gruen, 1985; 
Osweiler et al., 1985; NAS, 1977). Information about chronic 
effects, primarily from human epidemiological studies, 
associate arsenic with degenerative, inflammatory, and 
neoplastic changes of the skin, respiratory system, liver, 
cardiovascular system, blood, lymphatic system, nervous 
system, and reproductive system (Pershagen, 1983). Long term 
studies are needed to determine neoplastic effects of 
arsenic. This study was designed to determine the maxium 
dosage that a dog could tolerate in a chronic study. 
Numerous controlled subchronic and chronic inorganic 
arsenic studies have been done with rats and a lesser number 
with mice (Byron et al., 1967; Schroeder and Balassa, 1967; 
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Schroeder et al., 1968; Kiyono et al., 1974; Fowler et al., 
1977; Fowler and Woods, 1979). Inorganic arsenic adversely 
effects the weight or weight gain of rats and mice. More 
controlled chronic studies in higher animals are needed, 
especially since rats metabolize arsenic differently than 
other species studied (Ducoff et al., 1948; Lanz et al., 
1950; Klaassen, 1974). 
In limited studies inorganic arsenic also adversely 
affected the weight of pigs and dogs (Byron et al., 1967; 
Morrison and Chavez, 1983). Dogs chronically fed 0.5 or 2.0 
mg of arsenic per kg of body weight daily had no adverse 
effects (Calvery et al., 1938). The arsenic was in the form 
of finely powdered arsenic trioxide. In another study, dogs 
given feed containing 125 ppm of arsenic as sodium arsenate 
or sodium arsenite had significant weight loss (Byron et al., 
1967). Weight loss was more severe in the group fed 
arsenite. Dogs exposed to 50 ppm of arsenic of either 
compound were not affected. 
Feed or water is rejected by animals when it is 
contaminated by a high enough concentration of inorganic 
arsenic (Fowler and Woods, 1979; Morrison and Chavez, 1983). 
Therefore, feed rejection is probably the cause of the weight 
lost described above. 
Sodium arsenite was used in this study. It is one of 
the most toxic forms of inorganic arsenic because it is water 
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soluble and trivalent (Squibb and Fowler, 1983). 
The purpose of this study was to determine the dosage of 
dietary sodium arsenite that causes weight loss and whether 
the weight loss is a direct or indirect result of the 
arsenic. 
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MATERIALS AND METHODS 
Thirty female beagle dogs, 7 to 8 month old, were 
randomly assigned to 5 groups. Control, low dosage, medium 
dosage, and high dosage groups were offered 0, 1, 2, or 4 mg 
of sodium arsenite (NaAsOg) per kilogram of body weight in 
the feed daily. After 58 days, the dosage of all groups was 
doubled for the rest of the experiment. To account for 
substantial feed refusal in principals a pair fed group 
(inanition control) was fed the amount of feed, without 
sodium arsenite, that the high dosage group consumed on a 
percent body weight basis. Pairings were by group, not 
individual animals, and readjusted weekly to mimic intake of 
the high dosage group. 
Each dog of the control, low dosage, medium dosage, and 
high dosage groups was offered daily 2.75 percent of its body 
weight of dry Purina High Pro Dog Chow (Ralston Purina Co., 
St. Louis, MO) for the first 2 weeks, then 3.00 percent for 
the rest of the experiment. Feed samples were quantitated 
for arsenic by hydride atomic absorption spectroscopy (3 03 
Perkin-Elmer Atomic Absorption Spectrometer, Perkin-Elmer 
MHS-10 Hydride System, Perkin-Elmer Co., Norwark, Conn) 
according to methods previously described (Hyde et al., 
1977). Feed contained less than 0.1 ppm arsenic. Stainless 
steel feed and water bowls were used. Dry feed was mixed 
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with an equal weight of water containing the appropriate dose 
of sodium arsenite dissolved in it. The feed was weighed and 
mixed with arsenic every morning. Feed and water were mixed 
thoroughly to insure even distribution of arsenic in feed. 
The amount of water added wet the feed evenly, and no excess 
water was left free of the feed. The mixture was offered to 
the dog for 6 to 8 hours. Each night the unconsumed feed was 
weighed and recorded. The dogs had free choice tap water at 
all times. Tap water contained less than 0.01 ppm of 
arsenic. 
The dogs were housed individually in stainless steel 
cages (Shor-Line, Shroer Manufacturing Co., Kansas City, MO). 
Each unit consisted of 2 cages, one above the other. The 
assignment of dogs to cages was random except the bottom dog 
was always from the same group as the top dog. The dogs were 
observed at least 3 times a day, and the cages cleaned daily. 
Body weights were determined and the amount of feed and 
arsenic adjusted weekly. To decrease the effect of variation 
of individual body weights, the weekly body weight of a dog 
was divided by the initial body weight of that dog. The 
fraction of the initial body weight (FIBW) of each animal 
was used in the analysis of data. Therefore, the FIBW of all 
dogs on week 1 was 1. 
The experiment was divided into 3 phases (I, Ila and 
lib) on the basis of time and groups for analysis of the data 
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generated (Table 1). Phase I involved all groups from week 1 
through week 8. In phase I nominal dosages (intended dosage 
if dog consumed all feed offered to it) of sodium arsenite 
for control, low dosage, medium dosage, high dosage, and pair 
fed groups were 0, 1, 2, 4, and 0 mg per kg of body weight 
per day (mg/kg/day), respectively. Phase Ila consisted of 
all groups from weeks 9 through 17 at nominal dosages double 
that of phase I (0, 2, 4, 8, 0 mg/kg/day). At the end of 
phase lia, high dosage and pair fed groups were terminated 
when the high dosage group had lost approximately 20 percent 
of their original body weight (Figure 13). Phase lib 
consisted of control, low dosage, and medium dosage groups 
from week 9 to 26 at 0, 2, and 4 mg/kg/day, respectively. In 
all phases, the actual arsenic dosages were calculated daily 
by multiplying the percent of offered feed consumed by the 
appropriate nominal dosage. At the feeding rate of 3 percent 
of body weight per day, the phase I dosages were equivalent 
to 33.4, 66.7, and 133.4 ug of sodium arsenite per gm of dry 
feed for low, medium, and high dosage groups, respectively. 
Pair fed group was started on the experiment 20 weeks 
after the other groups. Therefore, the data for a certain 
experimental week was on the average collected 20 weeks 
later, real time, than data for other groups. An average age 
difference of 20 weeks existed between pair fed group dogs 
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and dogs of other groups. 
The experiment utilized a complete random design to 
compare groups with different treatments. Individual dogs 
were the experimental units. The time effect was a repeated 
measure and analyzed as a split plot factor. It was 
recognized that the week factor was a repeated measure and 
hence the significance levels of week and group by week 
interaction effects may have been exaggerated. However, we 
took account of this effect by using conservative degrees of 
freedom. Least significant differences were calculated from 
the experimental error of dogs within groups (Snedecor and 
Cochran, 1967). The data were analyzed using the SAS 
computer based system (SAS Institute Inc., Gary, NC). 
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RESULTS 
Pair fed group feed consumption data were not analyzed 
with the other groups because it was not independent of high 
dosage group data. A separate analysis of high dosage and 
pair fed groups showed no statistical difference in the feed 
consumption. 
High dosage group feed intake decreased significantly in 
week 1 relative to the week prior to arsenic exposure (Figure 
1). High dosage group week 1 intake was statistically less 
than that of control and low dosage groups (p<0.05). By week 
4, there was no significant difference among the groups. The 
other groups feed intake did not decrease relative to the 
control group. Linear regression of phase I feed consumption 
(Figure 2) demonstrated that the medium dosage group (p<0.05) 
and high dosage group (p<0.01) had significantly larger 
slopes than control and low dosage groups. The high dosage 
group slope was greater than the medium dosage group slope 
(p<0.01). 
In phase Ila, weeks 9 through 17, the dosage was doubled 
for all groups. Both medium and high dosage groups had 
decreases in feed intake from week 8 to 9 (Figure 3). During 
week 9, medium dosage group feed consumption was not 
significantly less than the controls (p<0.05). High dosage 
group feed consumption was significantly less than control, 
low dosage (p<0.01) and medium dosage groups (p<0.05). By 
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week 17, consumption in medium and high dosage groups 
increased. However, high dosage group intake was still 
significantly less than control group (p<0.05). Linear 
regression analysis of phase Ila data (Figure 4) showed all 
three arsenic exposed groups had statistically different 
(p<0.01) feed intake slopes than controls. Medium and high 
dosage groups had a positive slope and low dosage group a 
negative slope relative to control group. 
High dosage group was terminated on week 17. Control, 
low dosage, and medium dosage groups were continued through 
week 26 (phase lib. Table 1). The medium dosage group had 
reduced feed intake in week 9 (not statistically 
significant), but feed intake increased and approached the 
level of controls and low dosage groups by week 26 (Figure 
5). Linear regression slope of medium dosage group (Figure 
6) was significantly greater (p<0.01) than slope for control 
and low dosage groups. 
According to the experimental design, arsenic 
consumption was determined by the feed intake. The daily 
arsenic intake averaged over weeks was almost always 
significantly different among groups (largest p <0.05). The 
exceptions are between low and medium dosage groups in week 
10 and between medium and high dosage groups in weeks 9, 10, 
11, 12, 16 and 17. Average sodium arsenite consumption over 
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all of phase I was 0.0, 0.88, 1.80, 2.88, and 0.0 mg/kg/day 
for control, low dosage, medium dosage, high dosage, and pair 
fed groups, respectively. These overall averages are 
statistically different from each other (p<0.01). Arsenic 
consumption from week 1 to 8 was relatively constant for low 
and medium dosage groups. High dosage group sodium arsenite 
daily intake gradually increased through phase I. Linear 
regression for arsenic consumption in phase I (Figure 7) 
showed high dosage group consumption increased significantly 
(p<0.01). 
In phase Ila, the overall average daily sodium arsenite 
consumption was 0.0, 1.66, 2.86, 3.74, and 0.0 mg/kg/day for 
control, low dosage, medium dosage, high dosage, and pair fed 
groups respectively. The overall averages are statistically 
different (p<0.01). Linear regression (Figure 8) showed 
significant increases in medium and high dosage groups 
arsenic intake from week 9 to 17 (p<0.05 and p<0.01 
respectively). Low dosage group intake (p<0.05) decreased 
over the same period. In week 11, medium and high dosage 
groups consumed similar amounts of arsenite (2.77 and 2.83 
mg/kg/day respectively) because of severe feed rejection by 
the high dosage group. 
Control, low dosage, and medium dosage group average 
daily sodium arsenite consumption for phase lib was 0.0, 
1.59, and 3.00 mg/kg/day respectively. Average arsenic 
58 
intake amoung groups for phase lib was statistically 
different (p<0.01). Arsenic intake decreased for the low 
dosage group and increased for the medium dosage group from 
weeks 9 to 26. Linear regression analysis (Figure 9) of the 
low dosage group decrease and medium dosage group increase 
was significant (p<0.01). 
Sodium arsenite caused a dose dependent decrease in the 
FIBW. FIBW of the high dosage group decreased from week 0 to 
week 3 (Figure 10). From week 3 to week 8 the FIBW of the 
high dosage group leveled off and slightly increased. The 
linear regression of FIBW (Figure 11) over the first 8 weeks 
resulted in negative slopes for the high dosage and pair fed 
groups that were statistically similar and significantly less 
than those of other groups (p<0.01). Control, low dosage, 
and medium dosage groups had gradual weight gains over the 
same period that were not statistically different from each 
other. 
FIBW of the pair fed group increased during week 1 to 
1.050 then approximatley paralleled the weekly FIBW of high 
dosage group for the rest of phase I and Ila. This gave pair 
fed group a linear regression line higher than but almost 
parallel to that of high dosage group (Figures 11 and 12). 
In phase lia, control and low dosage groups continued to 
gain weight (Figure 13). Hence the linear regressions of 
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FIBW for these groups had positive slopes (Figure 12). 
Medium dosage group gradually lost weight and linear 
regression demonstrated a slightly negative slope. High 
dosage and pair fed groups lost weight faster than in phase I 
and had linear regression lines statistically parallel and 
with negative slopes. The regression slopes of medium 
dosage, high dosage, and pair fed groups were statistically 
less than those of control and low dosage groups (p<0.01). 
Slopes of high dosage and pair fed groups were significantly 
less than the slope of medium dosage group (p<0.01). 
In phase lib, medium dosage group gradually lost weight 
for the first half and then remained stable (Figure 14). 
This resulted in a linear regression line with a slightly 
negative slope (Figure 15). Both control and low dosage 
groups gradually gained weight over phase lib, hence both had 
positively sloped linear regression lines. Low dosage group 
gained less than control group and had a significantly 
(p<0.01) smaller slope. Slope for medium dosage group is 
statistically less than those for either control or low 
dosage groups (p<0.01). There was significant, unexplained, 
weekly variation of FIBW (p<0.01). 
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DISCUSSION 
Inorganic arsenic in the feed caused a dose dependent 
rejection of feed. Four mg/kg/day of sodium arsenite in the 
daily ration caused medium and high dosage groups to have 
decreases in feed intake the first week of phases Ila and I 
respectively. The high dosage group decrease was significant 
(p<0.05) and medium dosage group nearly significant (p>0.05, 
Figures 1 and 3). Eight mg/kg/day caused high dosage group 
to have a greater decrease (p<0.01) in intake than when it 
was first exposed to 4 mg/kg/day (Figure 3). All three 
decreases in feed intake were followed by a significant 
(p<0.01) increase of intake depicted by linear regression 
analysis (Figures 2 and 4). 
Feed intake of control and low dosage groups were not 
significantly different in phases I and lib (Figures 2 and 
6). In phase lia (Figure 4), the linear regression slopes of 
these groups was significantly different (p<0.05). When 
these data were reanalyzed with additional data in phase lib, 
there was no statistical difference. This supports the 
conclusion that exposure to 1 or 2 mg/kg/day of sodium 
arsenite does not have a significant effect on feed intake. 
In phase I, medium dosage group (2 mg/kg BW /day) had a 
significant feed intake increase over time relative to 
controls (Figure 2). Medium dosage group week 8 feed 
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consumption was greater (statistically not significant) than 
that of the controls (Figure 1). This would suggest that 
arsenic at this concentration stimulates feed intake. 
However, the low dosage group exposed to 2 mg/kg/day in phase 
lib did not exhibit the same change (Figure 6). 
Dogs tolerated nominal dosages of 1 and 2 mg/kg/day of 
sodium arsenite (Figures 2 and 6). It appears that after a 
certain arsenic concentration is reached, the arsenic 
controls feed intake. When high dosage group exposure to 
arsenic was increased from 4 to 8 mg/kg/day, the absolute 
amount of arsenic consumed was not markedly increased for 6 
weeks (Figures 7 and 8). This is because when arsenite 
concentrations were doubled for the high dosage group, the 
feed intake voluntarily reduced by half (Figure 3). Midway 
through phase Ila this trend reversed and the high dosage 
group started to gradually increase its intake. 
The linear regression analysis of FIBW over time 
demonstrates a significant (p<0.01) decrease in body weight 
when dogs are exposed to 4 or 8 mg/kg/day of sodium arsenite 
(Figures 11, 12, and 15). Control and low dosage groups 
gained weight over the same period. Weight loss has been 
demonstrated previously in pigs, mice, rats, and dogs exposed 
to inorganic arsenic (Calvery et al., 1938; Byron et al., 
1967; Fowler and Woods, 1979; Morrison and Chavez, 1983). 
Regression line slopes for FIBW of high dosage and pair 
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fed groups were statistically the same. This demonstrates 
that decreased feed intake, not the direct effect of arsenic, 
caused the weight decrease. In Figure 11, the regression 
line for pair fed group is higher than high dosage group. 
This was caused by the unexplained increase of FIBW for pair 
fed group in week 1. 
Hairless mice given 50 mg/liter of arsenic trioxide in 
the drinking water had an initial weight loss , but 
compensated over the following 15 weeks and achieved final 
weights similar to the controls (Bencko and Symon, 1969). 
Dogs in this study did not demonstrate this weight 
compensation. However, dogs offered 4 mg/kg/day had 
increasing feed intake after an initial decrease and if the 
study had been longer the decreased weights may have 
increased toward normal or control values. 
It is not known how arsenic causes feed rejection. 
Following is a hypothesis formed from some of our 
observations. 
The vomiting center of the medulla can be stimulated in 
5 basic ways: by the 1) gastrointestinal tract, 2) heart and 
other viscera, 3) chemoreceptor trigger zones, 4) labyrinth 
and 5) supramedullary sites of the central nervous system 
(Barnes, 1984). In our laboratory, we have observed that 
high dosages of oral inorganic arsenic caused vomiting. 
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Vomiting was also produced by parenteral administration of 
sodium arsenite solution. The gastrointestinal tract and 
chemoreceptor trigger zone would be logical routes for 
arsenic stimulation of the vomiting center. In the 
gastrointestinal tract, local receptors are stimulated and 
send a nerve impulse via afferent nerves to the vomiting 
center in the brain stem. However, since intravenous 
administration of inorganic arsenic induces vomiting, the 
blood arsenic could be stimulating receptors of the 
chemoreceptor trigger zone which in turn stimulates the 
vomiting center. The chemoreceptor trigger zone is located 
in the area postrema of the medulla oblongata. It is 
stimulated by blood-borne chemical substances that cause 
vomiting. Known examples are digitalis, apomorphine, 
morphine and bacterial toxins (Davis, 1980; Borison et al., 
1984) . 
We also subjectively observed taste aversion induced by 
feed contaminated with sodium arsenite. Dogs would eat a 
specific flavor of dog food once or twice when it contained 
large amounts of arsenite. Vomiting occurred shortly after 
ingestion. After one or two feedings, the dog would reject 
that type of dog food even if it did not contain arsenite in 
subsequent exposures. However, if feed type or flavor was 
changed the dog would eat it even if it contained arsenite. 
Taste aversion has been associated with the area postrema in 
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rats (Borison et al., 1984). Our observations of vomiting 
and taste aversion caused by arsenite are subjective and 
controled experiments should be done to verify them. 
Nausea in humans is the conscious awareness of unusual 
activity in the centers associated with vomiting mediated by 
the central nervous pathway (Barnes, 1984). If dogs 
experience nausea induced by low levels of ingested arsenic 
this may be the reason that our high dose group rejected a 
large portion of their feed. This seems a plausible 
explanation that should be explored. 
Another possible explanation of the lowered feed intake 
is that arsenic stimulated the satiety center of the brain 
stem and the dogs were not hungry (Sullivan and Gruen, 1985). 
High dosage dogs (8 mg/kg/day) were continually at the feed 
bowl, worrying, but not completely ingesting the daily feed 
offering. This suggests the dogs were hungry and the satiety 
center of the brain was not stimulated. 
Without specifically knowing the mechanism for the 
arsenic induced feed rejection, we suggest that rejection was 
due to blood borne arsenic stimulation of the chemorecptor 
trigger zone which excited the vomiting center and produced 
nausea without vomiting. Arsenic treated dogs in our study 
did not have more vomiting activity than controls. 
Gradual feed intake increasing after the initial 
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rejection of feed containing 4 or 8 mg/kg/day of sodium 
arsenite suggests that adaptation was occurring (Figures 2, 
4, and 6). If nausea was the cause of feed rejection, it is 
possible the dogs got so hungry that appetitive drive became 
the stronger behavioral stimulus. Feed aversion induced by 
illness in rats is weakened by increased hunger (Peters and 
Reich, 1973). 
Adaptation to arsenic does occur and has been shown 
experimentally to increase the arsenic LD q^ in mice 
chronically exposed to arsenic trioxide (Bencko and Symon, 
1969). This might be accomplished by decreased absorption or 
increased excretion of ingested arsenic. If either of these 
occurred, presumably blood arsenic levels would remain below 
a level that stimulates the chemoreceptor trigger zone. 
It has been shown in rats exposed to oral inorganic 
trivalent arsenic that there is an increase of glutathione in 
the intestinal mucosa. This could block systemic arsenic 
absorption by chelation (Pisciotto and Graziano, 1980). 
Adaptation due to increased excretion is possible. The 
largest portion of the body burden of inorganic arsenic is 
eliminated by the urine (Vahter, 1983). Chronic exposure of 
mice to low concentrations of inorganic arsenic in the water 
decreased organ arsenic retention after subsequent 
subcutaneous injection of arsenic (Bencko et al., 1973). 
Urinary excretion is more efficient when arsenic is 
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methylated (Marafante and Vahter, 1984; Marafante et al., 
1985). Fibroblasts in culture pretreated with low doses of 
trivalent arsenic increased biotransformation of inorganic 
arsenic to methylated forms (Fischer et al., 1985). This 
suggests that mammals adapt to arsenic by increased 
methylation and therefore increased urinary excretion. 
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TABLE 1 . 
Nominal Dosages^ in Study of Dogs 
Offered Sodium Arsenite Contaminated Feed 
Groupé 
Control Low Medium High Pair 
Dosage Dosage Dosage Fed 
Phase I (weeks 1-8) 0 12 4 0 
Phase Ila (weeks 9-17) 0 2 4 8 0 
Phase lib (weeks 9-26) 0 2 4 
^Mg of sodium arsenite offered daily per kg of body 
weight. 
^Six dogs in each group. 
°Pair fed amount of feed equal to high dosage group 
feed intake (without arsenic). 
Fig. 1. Average daily feed consumption as percent of body 
weight for selected weeks in phase I. Nominal dosages of 
sodium arsenite were 0, 1, 2, 4, and 0 mg/kg/day for 
control, low, medium, high, and pair fed groups 
respectively. High dose and pair fed group week 1 
consumption was significantly lower than that of controls 
(p<0.05). 
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Fig. 2. Linear regression of daily feed consumption as 
percent body weight over time in phase I. Nominal dosages 
of sodium arsenite were 0, 1, 2, 4, and 0 mg/kg/day for 
control, low, medium, high, and pair fed groups, 
respectively. Medium and high dose group slopes were 
significantly higher than that of controls (p<0.05 and 
p<0.01, respectively). 
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Fig. 3. Average daily feed consumption as percent of body 
weight for the last week of phase I and selected weeks in 
phase Ila. Nominal dosages of sodium arsenite were 0, 2, 
4, 8,and 0 mg/kg/day for control, low, medium, high, and 
pair fed groups respectively. Feed consumption of the 
high and pair fed groups were significantly lower than the 
controls in weeks 9, 13 (p<0.01), and 17 (p<0.05). 
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Fig. 4. Linear regression of daily feed consumption as 
percent body weight over time in phase Ila. Nominal 
dosages of sodium arsenite were 0, 2, 4, 8, and 0 
mg/kg/day for control, low, medium, high, and pair fed 
groups, respectively. Slopes for medium dose, high dose, 
and pair fed groups are significantly higher (p<0.01) and 
the slope of the low dose group lower (p<0.05) than that 
of controls. 
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Fig. 5. Average daily feed consumption as percent of body 
weight for selected weeks in phase lib. Nominal dosages 
of sodium arsenite were 0, 2, and 4 mg/kg/day for 
control, low, and medium dose groups respectively. No 
weekly group averages are significantly different. 
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Fig. 6. Linear regression of daily feed consumption as 
percent body weight over time in phase lib. Nominal 
dosages of sodium arsenite were 0, 2, and 4 mg/kg/day for 
control, low, and medium dose groups respectively. Medium 
dose group slope is significantly higher than slopes for 
low dose and control groups (p<0.01). 
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Fig. 7. Linear regression of actual daily sodium arsenite 
consumption as mg per kg of body weight over time in phase 
I. Nominal dosages of sodium arsenite were 0, 1, 2, and 4 
mg/kg/day for control, low, medium, and high dose groups, 
respectively. High dose group slope is significantly 
higher than slopes for low, medium, and control groups 
(p<0.01). 
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Fig. 8. Linear regression of actual daily sodium arsenite 
consumption as mg per kg of body weight over time in phase 
Ila. Nominal dosages of sodium arsenite were 0, 2, 4, and 
8 mg/kg/day for control, low, medium, and high dose 
groups, respectively. High and medium dose group slopes 
are significantly higher (p<0.01 and p<0.05 respectively) 
and low dose group slope significantly lower (p<0.05) than 
that of control group. 
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Fig. 9. Linear regression of actual daily sodium arsenite 
consumption as mg per kg of body weight over time in phase 
lib. Nominal dosages of sodium arsenite were 0, 2, and 4 
mg/kg/day for control, low, and medium dose groups, 
respectively. Medium dose group slope is significantly 
higher and low dose group slope significantly lower than 
that of control group (p<0.1). 
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Fig. 10. Average fraction of initial body weight for 
selected weeks in phase I. Nominal dosages of sodium 
arsenite were 0, 1, 2, 4, and 0 mg/kg/day for control, 
low, medium, high, and pair fed groups, respectively. No 
significant differences between the weekly averages were 
observed (p<0.05). 
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Fig. 11. Linear regression of the fraction of initial 
body weight over time in phase I. Nominal dosages of 
sodium arsenite were 0, 1, 2, 4, and 0 mg/kg/day for 
control, low, medium, high, and pair fed groups, 
respectively. High and pair fed group slopes were 
statistically similar and significantly lower than that of 
the other groups (p<0.01). 
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Fig. 12. Linear regression of the fraction of initial 
body weight over time in phase Ila. Nominal dosages of 
sodium arsenite were 0, 2, 4, 8, and 0 mg/kg/day for 
control, low, medium, high, and pair fed groups, 
respectively. High and pair fed group slopes were 
statistically similar and significantly lower than that 
other groups (p<0.01). Medium dose group slope was 
significantly lower than slopes of low dose and control 
groups (p<0.01). 
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Fig. 13. Average fraction of initial body weight for week 
8 and selected weeks in phase Ila. Nominal dosages of 
sodium arsenite were 0, 2, 4, 8, and 0 mg/kg/day for 
control, low, medium, high, and pair fed groups, 
respectively. Averages for high dose group during weeks 
14 and 17 are significantly lower than those of the 
controls (p<0.05). 
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Fig. 14. Average fraction of initial body weight for week 
8 and selected weeks in phase lib. Nominal dosages of 
sodium arsenite were 0, 2, and 4 mg/kg/day for control, 
low, and medium dose groups, respectively. No significant 
differences between the weekly averages are observed 
(p<0.05). 
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Fig. 15. Linear regression of the fraction of initial 
body weight over time in phase lib. Nominal dosages of 
sodium arsenite were 0, 2, and 4 mg/kg/day for control, 
low, and medium dose groups, respectively. The slopes of 
the low dose group and medium dose group are significantly 
lower than that of controls (p<0.01). Slope of medium 
dose group is significantly lower than that of low dose 
group (p<0.01). 
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ABSTRACT 
Thirty female beagle dogs, 7 to 8 months old, were 
assigned to 5 groups. Control, low dosage, medium dosage, 
high dosage, and pair fed groups were offered 0, 1, 2, 4, and 
0 mg of sodium arsenite per kg of body weight per day 
(mg/kg/day) respectively in their feed. On day 59 the dosage 
was doubled for the rest of the experiment which ended on day 
183. The pair fed group was offered the amount of feed that 
the high dosage group consumed. High dosage and pair fed 
groups were terminated in week 17 when the high dosage group 
had lost a cumulative average of 20 percent of their original 
body weight. Serum liver leakage enzymes aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) 
were elevated in treated groups relative to controls. Serum 
AST was elevated in dogs exposed to 4 and 8 mg/kg/day of 
sodium arsenite. Serum ALT was elevated in dogs exposed to 
2, 4, and 8 mg/kg/day. ALT and AST elevations relative to 
controls were persistent and low grade. Only ALT in the high 
dosage group was elevated above what is considered normal. 
Elevated serum ALT and AST indicates sodium arsenite causes 
altered hepatocyte plasma membrane permeability. 
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INTRODUCTION 
Arsenic is ubiquitous in nature and local concentration 
increases, caused by man, are common. Therefore, it is 
impossible to avoid arsenic exposure at some level. Past 
experimentation in dogs lacks detailed evaluation of the 
concentration at which dietary arsenic causes effects and 
what the effects are (Calvery et al., 1938; Byron et al., 
1967). Human epidemological studies have associated arsenic 
with a multitude of disorders involving almost every organ 
system of the body (Pershagen, 1983). Lesions range from 
hyperkeratosis of the skin to neoplasia of the liver. 
Controlled experimental studies have not as yet proven all 
the associations made by epidemological studies. Long term 
studies are needed to determine neoplastic effects of 
arsenic. This study was designed to determine the maxium 
dosage a dog could tolerate in a long term study without 
serious acute of chronic toxicosis. 
It is well established that inorganic arsenicals affect 
the function of a large number of enzymes within many 
metabolic systems. Replacement of PO^ with AsO^ in important 
biochemical compounds such as ATP has also been documented 
(Squibb and Fowler, 1983). Therefore it may be assumed all 
organ systems in the body could be affected by arsenic. 
In this study we monitored many organ systems repeatedly 
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by the use of a wide variety of clinical pathological 
methods. This was done to determine which organ systems are 
affected by dietary inorganic arsenic. 
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MATERIALS AND METHODS 
Thirty female, 7 to 8 month old, beagle dogs were 
randomly assigned to five groups. Control, low dosage, 
medium dosage, and high dosage groups were offered 0, 1, 2, 
or 4 mg respectively of sodium arsenite (NaAsOg) per kilogram 
of body weight in the feed daily (mg/kg/day). After 58 days 
the dosage of all groups was doubled for the rest of the 
experiment. To account for substantial feed refusal in 
principals a pair fed group (inanition control) was fed an 
amount of feed, without NaAsOg, that the high dosage group 
consumed on a percent body weight basis. Pairings were by 
group, not individual animals, and readjusted weekly to mimic 
intake of the high dosage group. 
Each dog of control, low dosage, medium dosage, and high 
dosage groups was offered daily 2.75 percent of their body 
weight of dry Purina High Pro Dog Chow (Ralston Purina Co., 
St. Louis, MO) for the first two weeks, then 3.00 percent for 
the rest of the experiment. Dry feed was mixed with an equal 
weight of water with the appropriate dose of sodium arsenite 
dissolved in it. The feed was weighed out and mixed with 
arsenic every morning. Feed and water were mixed thoroughly 
to insure even distribution of arsenic in feed. The amount 
of water added wet the feed evenly, and no excess water was 
left free of the feed. The mixture was offered to each dog 
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for 6 to 8 hours. Every night the unconsumed feed was 
weighed and recorded. Body weights were measured and the 
amount of feed and arsenic adjusted weekly. The dogs had 
free choice tap water at all times. 
The dogs were housed individually in Shore-Line 
stainless steel cages (Shroer Manufacturing Co., Kansas City, 
MO). Each unit consisted of two cages, one on the top of the 
other. The assignment of dogs to cages was random except the 
bottom dog was always from the same group as the top dog. 
The dogs were observed at least three times a day, and the 
cages cleaned daily. 
The experiment was divided, into three phases (I, Ila and 
lib) on the basis of time and groups for the purpose of 
proper analysis of the data generated. Phase I involved all 
groups from week 1 through week 8. In phase I nominal 
dosages (intended dosage if dog consumed all feed offered to 
it) of NaAsOg for control, low dosage, medium dosage, high 
dosage, and pair fed groups were 0, 1, 2, 4, and 0 mg/kg/day 
respectively. Phase lia consisted of all groups from weeks 9 
through 17 at nominal dosages double that of phase I (0, 2, 
4, 8, 0 mg/kg/day). At the end of phase Ila, high dosage and 
pair fed groups were terminated when the high dosage group 
had lost approximately 20 percent of their original body 
weight. Phase lib consisted of control, low dosage, and 
medium dosage groups from week 9 to 26 at 0, 2, and 4 
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mg/kg/day, respectively. 
Pair fed dogs were started on the experiment 20 weeks 
after the other groups. Therefore, the data collected for 
any experimental week from the pair fed group were on the 
average collected 20 weeks later, real time, than data from 
control, low dosage, medium dosage, and high dosage groups. 
An average age difference of 20 weeks existed between pair 
fed dogs and dogs of the other groups. 
Periodic blood, serum, and urine samples were taken from 
all dogs and analyzed for a wide range of parameters (Table 
1). Due to the early termination of 2 dogs, of the high 
dosage group, they were sampled on week 15. Because of 
extenuating circumstances the pair fed group was not sampled 
on the exact trial day as the other groups. Urine was 
collected by transabdominal cystocentesis and every attempt 
was not successful due to empty bladders. At times it was 2 
days before an attempt was successful so samples from 
different dogs were secured within a period of 2 to 3 days. 
Serum samples were taken at the same time urine samples were 
secured. 
The following determinations were made on blood: packed 
cell volume (PCV) (Autocrit Ultra 3, Clay Adams, Becton 
Dickinson and Co., Parsippany NJ), total (WBC) (ZBI Coulter 
Counter, Coulter Electronics, Inc., Hialeah FL) and 
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differential (DIFF) white blood cell count (Ames Hemotech 
Slide Stainer, Ames Division, Miles Laboratories, Inc., 
Elkhart, IN), hemaglobin (HGB) (Coulter Hemoglobinometer, 
Coulter Electronics, Inc., Hialeah FL), total plasma protein 
(TPP), and fibrinogen (FIB) (TPP and FIB were measured on a 
standard T-S Meter, American Optical Company, Buffalo, NY). 
Difference between refractometer readings of heated (56° C 
for 3 minutes) and unheated plasma was calculated as FIB 
content. In addition partial thromboplastin time (PTT) and 
prothrombin time (PT) were measured in control and high 
dosage groups after 1, 6, and 12 weeks on trial (Hyland 
Clotek Fibrometer, Hyland Diagnostics Division, Cooper 
Diagnostics, Malvern PA). 
TM The serum was analyzed for urea nitrogen (BUN) (S.V.R. 
BUN Test Kit, Calbiochem-Behring, La Jolla, CA), total 
bilirubin (TB), direct bilirubin (DB) (Serosonic Bilirubin 
Test Kit, Mallinckrodt Inc. St Louis, MO), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
TM 
alkaline phosphatase (ALP) (S.V.R. AST, ALT, and ALP Test 
Kits, Calbiochem-Behring, La Jolla, CA) and albumin (ALB) 
(BCG reaction, Pierce reagents, Pierce Chemical Company, 
Rockford, IL). Additional blood was collected in sodium 
fluoride oxalate for evaluation of plasma glucose (GLU) 
(S.V.R.™ GLU Test Kit, Calbiochem-Behring, La Jolla, CA) 
All photometric tests were run on a chemistry auto-analyzer 
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(Rotochem lia; American Instrument Company, Silver Spring, 
MD) 
Urine was checked for glucose, blood, ketones 
(acetoacetic acid), bilirubin, urobilinogen, protein, and pH 
(Multistix, Ames Division, Miles Laboratories, Inc., Elkhart, 
IN). Urine ALP was evaluated with method noted above. Urine 
ALP to urine creatinine ratios were calculated to eliminate 
the effect of urine concentration from the data analysis. 
The specific gravity of every urine sample was measured with 
a standard T-S Meter (American Optical Company, Buffalo, NY). 
Urine osmolality was also measured (Osmette A Osmometer, 
Precision Systems, Natick MA). 
Concentrations of Na, K, CI, P, and creatinine (CRT) 
were determined in the urine and serum of every animal for 
every test period. Serum Ca determinations were also done. 
Na and K were measured with flame photometry (343 Flame 
Photometer: Instrumentation Laboratory, Inc., Lexington, MA) 
and CI by AgCl precipitation (Corning Model 92OM Chloride 
Meter: Corning Scientific Instruments, Medfield, MA). Ca 
and P determinations were made on a chemistry auto-analyzer 
(Rotochem Ila: American Instrument Company, Silver Spring, 
MD) using the Worthington Inorganic Phosphorus Reagent Set 
(Worthington Diagnostic Systems, Inc., Freehold, NJ) and the 
cresolphthalon complexone-diethylamine reaction with Ca. 
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GilChem reagents (Ciba Corning Diagnostics, Oberlin OH) were 
used in creatinine determinations to produce a picrate-
creatinine color producing complex which was measured by a 
spectrophotometer (Gilford 103 Spectrophotometer, ciba 
Corning Diagnostics, Oberlin OH). This method removes 
pseudocreatinine from the determination. 
Simultaneous serum and urine values were used to 
calculate the percent clearance ratios of Na, K, Cl, and P. 
Percent clearance ratio is defined by the following formula; 
PCR of X = [ (X^i/^sr) / ((^^ur/^^sr) ^ 
where is the concentration of substance X in the urine, 
Xg^ is the concentration of substance X in the serum, CR^^ is 
the concentration of creatinine in the urine, and CR^^ is the 
concentration of creatinine in the serum. Dogs secrete a 
small amount of creatinine from the renal proximal tubules. 
Creatinine secretion is greater in males and its clearance 
overestimates the glomerular filtration rate (Robinson et 
al., 1974). For this reason females were used. 
The experiment was of complete random design used to 
compare groups of different treatments. Individual dogs were 
the experimental units. Least significant differences (LSD) 
were calculated from the experimental error of dogs within 
groups (Snedecor and Cochran, 1967). The data were analyzed 
using the computer based Statistical Analysis Systems (SAS 
Institute Inc., Cary, North Carolina). 
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The blood, serum, and urine values of Phases I, Ila, and 
lib were analyzed separately. Values for phases I and lia 
were analyzed via the dog means for that phase without 
consideration of time since there were only 2 samples taken 
per dog in each phase. This was not enough for a valid 
analysis of the time factor. Phase lib data were analyzed 
with consideration of the time by group interaction. In 
analysis of phase lib it was recognized that the time factor 
was a repeated measure and hence the significant levels of 
time by group effects may have been exaggerated. However, we 
took account of this effect by using conservative degrees of 
freedom when determining the probability of greater F values. 
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RESULTS 
Dietary arsenite caused a statistically significant 
dosage dependent decrease in feed consumption and body weight 
(Neiger and Osweiler, 1987). Normal ranges used in this 
paper were defined by Duncan and Prasse (1986). 
All group mean blood values were within the normal 
range. Blood values other than FIB of treated groups were 
not significantly different from controls. FIB was 
significantly elevated relative to controls in high dosage 
and pair fed groups in phase Ila (Table 2). Pair fed group 
elevation was significantly higher than that of high dosage 
group. 
Mean PT and PTT combined values for control and high 
dosage dogs were 8.6 and 16.5 seconds respectively. There 
was no statistically significant difference between these 
groups (p>0.05). 
All group mean serum values except ALT were within the 
normal range. No differences in serum creatinine, glucose, 
total bilirubin, direct bilirubin, and alkaline phosphatase 
were present among groups. Group differences were present in 
ALB, BUN, AST, and ALT levels. Phase lia BUN levels of pair 
fed animals were depressed relative to controls (p=0.01). 
Serum ALB was elevated in medium dosage, high dosage, and 
pair fed groups in phase I (p=0.03). In phase lia, high 
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dosage and pair fed groups had depressed serum ALB (p=0.03). 
In all phases AST and ALT were elevated in one or more 
treated groups (Table 3). Serum AST values were 
significantly elevated in high dosage dogs in phases I and 
Ila (p<0.05) and medium dosage dogs in phases Ila and lib 
(p<0.01). Serum ALT values were significantly elevated in 
low dosage dogs in phase lib (p<0.05), medium dosage dogs in 
phase lib (p<0.01), and high dosage dogs in phase I and Ila 
(p<0.01). Pretreatment mean values for ALT and AST were 24 
and 19 lU/L respectively. There was no statistically 
significant difference between pretreatment values of control 
and treated groups. 
Urine blood, ketones, urobilinogen, protein, pH, 
specific gravity, and osmolality were within the normal range 
and no significant differences were present among groups. 
Urine bilirubin for the pair fed group was significantly 
elevated in phase I (p=0.01). In this period each dog was 
sampled twice (Table 1). Three of 6 pair fed dogs in this 
period had 1 sample which tested +1 or +2 and the other 
tested 0. All other dogs of all groups tested 0 on both 
samples. 
Urine glucose was elevated in pair fed dogs during phase 
Ila. As was the case for urine bilirubin in phase I, 3 of 
the 6 pair fed dogs had 1 of 2 urine samples test O.lg/dl and 
the other 0. All other dogs of other groups tested 0 in both 
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samples. 
Urine ALP of the low dosage group was significantly 
elevated relative to controls in phase lia and lib (p=0.01 
and p<0.05 respectively). No other group in any phase varied 
significantly from controls. Analysis of urine ALP expressed 
as raw data or urine ALP / urine CRT showed that the low 
dosage group deviated from controls. Mean urine ALP to CRT 
ratios for control and low dosage groups for phase lia were 
1.2 and 2 lU/g and for phase lib were 1.1 and 1.6 lU/g 
respectively. 
No significant difference in serum CI was present among 
groups. Serum Na for low and medium dosage groups in phase I 
was increased significantly over control group (p<0.05). 
Phase I serum Ca was increased in the medium dosage group 
(p<0.05) and decreased in pair fed group (p<0.01) relative to 
controls. Phase lia serum Ca of high dosage and pair fed 
dogs was significantly lower than that of control dogs 
(p<0.01 and p<0.05 respectively). Mean serum Ca for medium 
dosage was also lower than controls but not significantly. 
In phase lib, the medium dosage group had lower serum Ca than 
the control group (p<0.01). Serum P values of pair fed dogs 
in phases I and lia were lower than those of control dogs 
(p<0.01). Low dosage and medium dosage groups in phase lib 
had higher serum K than the controls (p<0.01). Mean serum K 
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values were 4.2, 4.5, and 4.5 for control, low dosage, and 
medium dosage dogs respectively. The LSD was 0.29 (p=0.01). 
PCRs for Na, K, P, and CI were not significantly 
different among groups in any of the 3 phases. 
The phase lib analysis of time by group interaction 
showed no significant treatment effect in any of the 
parameters measured. 
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DISCUSSION 
FIB in phase lia was elevated in both high dosage and 
pair fed groups. Therefore arsenic can be ruled out as the 
cause. This increase was not above what is considered high 
normal. A major common factor in these groups was limited 
feed intake. It is not apparent how reduced feed intake 
could cause the increase. Normal TPP values for the same 
time period eliminates dehydration as a cause (Table 2). 
Inflammation is a common cause of fibrinogen elevation. 
However neither group had a differential leukocyte count that 
suggested inflammation. The increase was more severe in the 
pair fed group. Two factors may account for this. One, the 
pair fed dogs were 20 weeks older than high dosage dogs, and 
2 they were on test 20 weeks later than the other dogs. The 
reason for the FIB elevation was not determined. 
Elevated urine bilirubin was not an arsenic effect since 
no treated group had elevated levels. Because the pair fed 
group was tested later than the others and animals that had 
positive values were negative on other sampling dates and 
since there was no evidence of elevated serum bilirubin we 
concluded the elevation was not significant. For the same 
reasons the same conclusion was made regarding the pair fed 
group urine glucose elevation. 
BUN of pair fed animals in phase Ila was lower than 
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other groups but within normal limits. In the same time 
period, serum creatinine was not significantly different 
between groups indicating that renal function was not the 
cause of the depression. Diminished protein intake can cause 
decreased BUN (Finco, 1980). Inadequate caloric intake 
causes increased protein catabolism and increased BUN (Finco, 
1980; Duncan and Prasse, 1986). Considering these facts a 
possible senerio is that pair fed dogs were given a limited 
feed intake, therefore protein was limited and BUN decreased. 
However, high dosage dogs feed intake was the same as pair 
fed dogs but their BUN did not decrease. High dosage dogs 
were 20 weeks younger and had considerably less fat reserve 
than the pair fed dogs going into the trial. Therefore, high 
dosage dogs had to catabolize structural protein for energy. 
Hence, factors that caused decreased BUN and increased BUN 
may have neutralized each other. It is clear arsenic had no 
direct effect on BUN levels. 
All serum albumin values were within normal limits, 
however significant differences were found amoung groups. In 
phase I serum albumin elevation was significant in medium 
dosage, high dosage and pair fed groups relative to controls. 
Kaneko (1980) states that true overproduction of albumin has 
not been known to occur in any animal. Since elevated values 
are still within the normal range, we conclude the difference 
is random variation. In phase Ila, high dosage and pair fed 
120 
groups had severely limited feed intake and significant 
decrease in serum albumin. Dietary malnutrition causes serum 
albumin depression (Duncan and Prasse, 1986). Since the pair 
fed group was not given arsenic, decreased serum albumin is 
not a direct effect of arsenic. 
Urine ALP to CRT ratio elevations in the low dosage 
group was peculiar to that group and not an arsenic effect. 
This conclusion was reached because no other treated group 
had elevated values and a low dosage group pretrial urine 
sample had an elevated ratio (mean=4 lU/g). 
Liver leakage enzymes AST and ALT were significantly 
elevated in serum of dogs treated with sodium arsenite. ALT 
values for the high dosage group were above the upper normal 
limit of 66 lU (Table 3). ALT is specific for the liver in 
dogs and is found normally free in the cytosol. AST is 
present in cytosol and mitochondria of many tissues 
(Cornelius, 1980). These enzymes are found in high 
concentrations within the normal cell. Serum levels increase 
when plasma membranes are altered and allow enzyme leakage 
(Duncan and Prasse, 1986). 
Elevated serum enzymes in this study indicate that 
sodium arsenite causes altered hepatocyte plasma membrane 
permeability. Serum AST and ALT increases were low grade and 
consistent. Since AST and ALT have short serum half-lives 
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(1-3 days), this indicates hepatocyte damage was persistent 
(Duncan and Prasse, 1986). 
Arsenic has an inhibitory effect on a multitude of 
enzymes, many of which could ultimately cause dysfunction of 
the plasma membrane (Webb, 1966). Reaction of arsenic with 
glutathione is a likely mechanism that would allow plasma 
membrane damage. Trivalent arsenic binds to many biological 
compounds which contain sulfhydryl groups. Glutathione 
reacts via sulfhydryl groups with cellular oxygen metabolites 
and lipid peroxides and prevents them from causing damage to 
the plasma membrane (Cheville, 1983). Binding of glutathione 
sulfhydryl groups to arsenic would effectively inhibit an 
important cellular antioxidation system. Pretreatment of 
animals with glutathione protected them from the toxic 
effects of arsenic (Voegtlin, 1925). 
Canine exposure to sodium arsenite in the field causes 
an elevation of ALT (Evinger and Blakemore, 1984). However, 
serum AST was reduced in rats exposed to 50 mg/kg of arsenic 
as dietary arsenate (Mahaffey et al., 1981). This 
discrepancy may be due to the fact that rats and dogs 
metabolize arsenic differently (Vahter, 1983). Rats 
accumulate arsenic in the blood with a half-life of 60 to 90 
days compared to a half-life of hours in the dog. This high 
blood arsenic in the rat may have interfered with measurement 
of serum enzymes. 
122 
Increased serum Na of low and medium dosage groups in 
phase I was not repeated by these or other groups in the rest 
of the experiment. This indicates that treatment was not the 
cause. Increased values were well within the normal range. 
The reason for these changes was not determined. 
The increase of serum K in phase lib of low and medium 
dosage groups was not repeated by these or other groups in 
the rest of the experiment. Increased serum K values were 
well within the normal range. It is doubtful this was a 
treatment effect, since no treated group in phase I or Ila 
had this change. However, treatment effect can not be ruled 
out. If it was a treatment effect, the pathophysiological 
mechanism for it is unknown. 
The decrease of serum P in pair fed dogs was probably 
due to their age. Young animals have higher serum P values 
than adults (Duncan and Prasse, 1986). Pair fed dogs were 20 
weeks older than the other dogs. 
Phase I serum Ca elevation in medium dosage dogs and 
depression in pair fed dogs is unexplained. However, mean 
serum Ca of control and low dosage dogs decreased in each 
sequential phase (11.4, 11.2, and 11.0 mg/dl in phases I, 
Ila, and lib respectively). Therefore the fact that pair fed 
dogs were 20 weeks older than the other dogs may explain why 
they had lower serum Ca values. 
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Serum Ca depression in high dosage and pair fed groups 
of phase Ila and medium dosage group in phase lib could have 
been caused by decreased serum albumin (Duncan and Prasse, 
1986). The medium group mean serum albumin of 3.7 g/dl was 
not statistically lower but considerably lower than that of 
the control group (4.5 g/dl). 
In conclusion, dietary inorganic arsenic at these levels 
caused no renal dysfunction that was detectable by multiple 
parameters measured. This study indicates that dietary 
sodium arsenite causes low grade persistent damage to 
hepatocyte plasma membranes. 
124 
REFERENCES 
Cheville, N. F. (1983). Cell Pathology. Iowa State 
University Press, Ames, Iowa. 
Cornelius, C. E. (1980). Liver Function. In Clinical 
Biochemistry of Domestic Animals (J. J. Kaneko, ed.), pp 
201-250, Academic Press, New York. 
Duncan, J. R. and Prasse, K. W. (1986). Veterinary 
Laboratory Medicine. Iowa State University Press, Ames, 
Iowa. 
Evinger, J. V. and Blakemore, J. C. (1984). Dermatits in 
dog associated with exposure to an arsenic compound. J. 
Am. Vet. Med. Assoc. 184, 1281-1282. 
Finco, D. R. (1980). Kidney function. In Clinical 
Biochemistry of Domestic Animals (J. J. Kaneko, ed.), pp 
338-394. Academic Press, New York. 
Kaneko, J. J. (1980). Serum proteins and the 
dysproteinemias. In Clinical Biochemistry of Domestic 
Animals (J. J. Kaneko, ed.), pp. 97-116. Academic Press 
New York. 
Mahaffey, K. R., Capar, S. G., Gladen, B. C., and Fowler, 
A. (1981). Concurrent exposure to lead, cadmium, and 
arsenic. Lab. Clin. Med. 98, 463-481. 
Neiger, R. D. and Osweiler, G. D. (1987). Effect of low 
level dietary sodium arsenite of feed intake and body 
125 
I 
weight of dogs. Section I, In Ph.D. Dissertatton—i(R. D. 
Neiger), Iowa State University, Ames, Iowa. 
Pershagen, G. (1983). The epidemiology of human arsenic 
exposure. In Biological and Environmental Effects of 
Arsenic (B. A. Fowler, ed.), pp. 199-232. Elsevier, New 
York. 
Robertson, T., Harbison, M., and Bovee, K. C. (1974). 
Influence of reduced renal mass on tubular secretion of 
creatinine in the dog. Am. J. Vet. Res. 35, 487-491. 
Snedecor, G. W. and Cochran, W. G. (1967). Statistical 
Methods. Iowa State University Press, Ames, Iowa. 
Squibb, K. S. and Fowler, B. A. (1983). The toxicity of 
arsenic and its compounds. In Biological and Environmental 
Effects of Arsenic (B. A. Fowler ed.), pp. 233-270. 
Elsevier, New York. 
Vahter, M. (1983). Metabolism of arsenic. In Biological 
and Environmental Effects of Arsenic (B. A. Fowler ed.). 
pp. 171-193. Elsevier, New York. 
Voegtlin, C. (1925). The pharmacology of arsphenamine 
(salvarsan) and related arsenicals. Physiol. Rev. 5, 63-
94. 
Webb, J. L. (1966). Enzyme and Metabolic Inhibitors. 
Academic Press, New York. 
126 
TABLE 1 
Blood, Serum, and Urine Sampling Schedule of Dogs 
Exposed to Dietary Sodium Arsenite 
Weeks on Trial 
Group 2 3 6 7 11 13 15 17 19 26 
Control X X X X X 
Low dosage X X X X X 
Medium dosage X X X X X 
High dosage X X X X^ X^ 
Pair fed X X X X 
®Two of 6 dogs. 
^Four of 6 dogs. 
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TABLE 2 
Mean Fibrinogen and Total Plasma Protein Values 
for Phase Ila of Dogs Exposed to Dietary Asenite 
Groups 
Control Low Medium High Pair Fed 
Fibrinogen 133 ISO 158 192^ 258^ 
(mg/dl) 
Total Plasma 6.3 6.3 6.5 5.9 6.3 
Protein (g/dl) 
^Significantly elevated relative to controls (p=0.05). 
^Significantly different from all other groups (p=0.05). 
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TABLE 3 
Mean Serum AST^ and ALT^ Values^ of Dogs 
Exposed to Dietary Sodium Arsenite in Phases I, Ila, and lib 
AST ALT 
Group I lia lib I lia lib 
Control 18 17 16 29 24 23 
Low dosage 21 19 20 37 42 44* 
Medium dosage 22 29** 29** 27 42 45** 
High dosage 
* * ** ** 
26 26 98 84 
Pair fed 16 15 23 22 
^Aspartate aminotransferase. 
^Alanine aminotransferase. 
°Given in lU/L. 
"k 
Statistically different than controls (p<0.05). 
Statistically different than controls (p<0.01). 
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ABSTRACT 
Thirty female beagle dogs, 7 to 8 months old, were 
assigned to 5 groups. Control, low dosage, medium dosage, 
high dosage, and pair fed groups were offered daily 0, 1, 2, 
4, and 0 mg of dietary sodium arsenite per kg of body weight 
respectively. On day 59 the dosage was doubled for the rest 
of the experiment which ended on day 182. The pair fed group 
was offered the amount of feed that the high dosage group 
consumed on a percent body weight basis. High dosage and 
pair fed groups were terminated in week 17 because the high 
dosage group had lost a cumulative average of 20 percent of 
their original body weight. No gross or light microscopic 
lesions were present in any group. Hepatocyte glycogen 
content was abundant and not significantly different among 
control, medium dosage, high dosage, and pair fed groups. 
Hepatocyte lipid content was limited and not different 
between control and high dosage groups. Electron microscopic 
evaluation of control and high dosage group livers was done. 
Hepatocyte mitochondrial volume density was increased in the 
treated group by 22 percent. Individual mitochondrial 
perimeters and maximum diameters were significantly increased 
in the treated group. Mitochondrial circularity shape factor 
was significantly decreased in treated animals. This study 
shows that dietary sodium arsenite in dogs causes enlargement 
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of hepatocyte mitochondria. Evidence presented supports the 
conclusion that mitochondrial enlargement is arsenic induced 
swelling. 
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INTRODUCTION 
Arsenic is ubiquitous in the environment and exposure is 
virtually impossible to avoid. In addition to natural 
sources the frequent use of arsenicals as herbicide and 
insecticidal bait creates the potential for accidental 
exposure to higher concentrations of arsenic. Arsenic has 
long been associated with liver damage (Soffer et al., 1937; 
Von Glahn et al., 1938; Finner and Calvery, 1939). There 
have been a few controlled studies of the effects of chronic 
low level arsenic exposure on dogs (Calvery et al., 1938; 
Byron et al., 1967). Significant inanition was produced at 
125 ug/gm dietary arsenic as sodium arsenite or sodium 
arsenate (Byron et al., 1967). However, no gross or light 
microscopic liver changes were noted. Electron microscopic 
examination of liver was not done on dogs in the above 
mentioned studies. 
Rats given access to drinking water containing 40 ug/gm 
of arsenic as sodium arsenate had a 1.2 fold increase in 
hepatocyte mitochondrial volume density (Fowler et al., 
1979). Nuclei and vacuole volume densities were not changed 
and lysosome volume density was significantly decreased. 
Mice given access to drinking water with 85 ug/gm arsenic as 
sodium arsenate had no significant change in hepatocyte 
volume densities of mitochondria , nuclei, vacuoles , or 
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lysosomes (Fowler and Woods, 1979). Rats metabolize arsenic 
differently than other species (Vahter, 1983). To better 
understand the pathological mechanisms of arsenic it is 
important to know if hepatocyte intracellular organelles of 
other species react morphologically as they do in the rat or 
mouse. 
Sodium arsenite is a trivalent arsenical that is 
relatively water soluble; therefore it is more toxic than 
most other arsenicals (Franke and Moxon, 1936; Harrisson et 
al., 1958; Savchuck et al., 1960). Sodium arsenite was 
selected for this study because of its high toxicity and its 
common occurrence in commercial chemicals and pesticides. 
The purpose of this study was to evaluate the gross, 
light microscopic, and electron microscopic liver changes in 
dogs exposed to low level subchronic dietary inorganic 
arsenic. 
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MATERIALS AND METHODS 
Thirty female beagle dogs, 7 to 8 months old, were 
randomly assigned to 5 groups (6 dogs per group). Control, 
low dosage, medium dosage, and high dosage groups were 
offered nominal dosages (intended dosage if dog consumed all 
feed offered to it) of 0, 1, 2, or 4 mg of sodium arsenite 
(NaAsOg) per kilogram of body weight in the feed daily. 
After 58 days the dosage of all groups was doubled for the 
rest of the experiment. To account for substantial feed 
refusal in principals a pair fed group (inanition control) 
was fed the amount of feed, without sodium arsenite, that the 
high dosage group consumed on a percent body weight basis. 
Pairings were by group, not individual animals, and 
readjusted weekly to mimic intake of the high dosage group. 
The pair fed group was started on the experiment 20 weeks 
after the other groups. Dogs of the pair fed group were on 
average 20 weeks older than dogs of other groups. 
Each dog of the control, low dosage, medium dosage, and 
high dosage groups was offered daily 2.75 percent of its body 
weight of dry dog food (Purina High Pro Dog Chow, Ralston 
Purina Co., St. Louis, Missouri) for the first 2 weeks, then 
3.00 percent for the remainder of the experiment. At the 
feeding rate of 3 percent of body weight per day, initial 
nominal dosages are equivalent to 33.4, 66.7, and 13 3.4 ug of 
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sodium arsenite per gm of dry feed as fed for low, medium, 
and high dosage groups respectively. Uncontaminated feed 
samples were quantitated for arsenic by hydride atomic 
absorption spectroscopy (303 Perkin-Elmer Atomic Absorption 
Spectrometer, Perkin-Elmer MHS-10 Hydride System) according 
to methods previously described (Hyde et al., 1977). Feed 
contained less than 0.1 ug/gm arsenic. 
Dry feed was mixed with an equal weight of tap water 
containing the appropriate dissolved dose of sodium arsenite. 
Feed and water were mixed thoroughly to insure even 
distribution of arsenic in feed. The amount of water added 
wet the feed evenly, and no excess water was left free of the 
feed. Feed was weighed and mixed with arsenic every morning. 
The mixture was offered to each dog for 6 to 8 hours. Each 
night, unconsumed feed was weighed, recorded, and discarded. 
The actual arsenic dosages were calculated daily by 
multiplying the percent of offered feed consumed by the 
appropriate nominal dosage. Body weights were determined and 
the amount of feed and arsenic adjusted weekly. The dogs had 
free choice tap water at all times. Tap water contained 
less than 0.01 ppm of arsenic. Feed and water were offered 
in stainless steel bowls. 
The dogs were housed individually in stainless steel 
cages (Shor-Line, Shroer Manufacturing Co., Kansas City, 
Missouri). Each unit consisted of 2 cages, one above the 
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other. The assignment of dogs to cages was random except the 
bottom dog was always from the same group as the top dog. 
The dogs were observed at least 3 times a day, and the cages 
cleaned daily. 
At the end of week 17, high dosage and pair fed groups 
were terminated because the high dosage group dogs had lost 
approximately 20 percent their original body weight. 
Control, low dosage, and medium dosage groups were terminated 
after 26 weeks. 
Livers of all dogs were evaluated grossly and with the 
light microscope. Control and high dosage groups were also 
examined with the electron microscope. 
Dogs were anesthetized with pentobarbital. A small (5-6 
cm ) specimen was collected from deep in the right medial 
lobe of the liver and immersed in 10% neutral buffered 
formalin. For control and high dosage group animals, part of 
the specimen was diced to approximately 1mm and immersed in 
3 % glutaraldehyde/0.IM cacodylate buffer at pH 7.2. Animals 
were then euthanized with an overdose of pentobarbital and a 
complete postmortem was performed. The liver was examined 
grossly and weighed after nonhepatic tissue was removed. 
Liver for light microscopic examination was taken from 
10% neutral buffered formalin, processed by standard paraffin 
techniques (AFIP, 1960), sectioned at 5 um, and stained with 
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hematoxylin and eosin. To evaluate glycogen content, two 
paraffin sections from each dog of control, medium dosage, 
high dosage, and pair fed groups were made. One section from 
each dog was stained with periodic acid Schiff (PAS). The 
other section was treated with diastase and then stained with 
PAS. To evaluate lipid content, frozen sections of formalin 
fixed tissue of each dog in the control and high dosage 
groups were stained with oil red 0. All light microscopic 
evaluation was done without knowledge of treatment group. 
Slides evaluated for glycogen and fat content were graded on 
a scale of 1 to 10 in ascending order as content increased. 
Tissue saved for electron microscopic evaluation was 
removed from the glutaraldehyde/cacodylate buffer after one 
hour and rinsed in pH 7.2 cacodylate buffer (O.IM). Then it 
was post fixed in 1% Osmium tetraoxide/0.IM cacodylate buffer 
for one hour. After several rinses in distilled water the 
specimens were dehydrated in acetone, infiltrated with 
acetone resin, dried, embedded and cured. Three randomly 
selected blocks of embedded tissue from each dog were 
sectioned (60-90 nm thick) and stained with 2% methanolic 
uranyl acetate and Reynolds' lead citrate (Reynolds, 1963). 
With the use of a transmission electron microscopic (HS-9, 
Hitachi Ltd., Tokyo, Japan) the upper left corner of the 
first three upper left complete grid spaces that contained 
hepatocytes were photographed. Final magnification of the 
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electron micrographs was 15,890. Total number of micrographs 
per dog was 9. 
Stereological methods were used to compare liver 
ultrastructure of control and high dosage groups. Profiles 
of the ultrastructure of the hepatocytes were traced onto 
transparencies which were analyzed by a computerized image 
analysis system (Zeiss SEM-IPS Image Analysis System, Carl 
Zeiss Inc., Thornwood, New York). Volume and surface 
densities of nuclei, fat globules, mitochondria, and 
lysosomes (primary and secondary) were measured (Weibel, 
1979). Volume density is the relative volume of an object of 
interest within a given reference volume. Surface density is 
the surface area of an object of interest within a 
corresponding reference volume. In this study, objects of 
interest were nuclei, fat globules, mitochondria, and 
lysosomes. Reference volume in all cases was hepatocyte cell 
volume. The formula for volume density (V^) is; 
Vp = A / RefA 
where A = sum of area of profiles of interest and RefA = 
reference area. The surface density (S^) formula is: 
Sp = 4P / 3.14RefA 
where P = sum of perimeter of profiles of interest. V^ and 
S^ were calculated with data summed over electron micrographs 
from blocks of tissue. Calculated V^ and S^ values were 
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statistically analyzed as repeated measures from the 
experimental unit (dog). The number of mitochondrial 
profiles per reference area was counted. 
Two dimensional characteristics of individual hepatocyte 
mitochondria of control and high dosage groups were measured. 
Measurements were made from the transparencies made for the 
stereological procedure. Measurements included area, 
perimeter, circularity shape factor, equivalent circular 
diameter, maximum diameter, and minimum diameter (Schwarz, 
1980). Circularity shape factor (Cirsf) of a circle is 1. 
As the shape of an object becomes elongate or more irregular 
the Cirsf gets progressively less. The formula for Cirsf is: 
Cirsf =4 (3.14) (Ap)/0Pp2 
where Ap = area of an individual mitochondrial profile and 
OPp = outside perimeter of an individual mitochondria 
profile. Equivalent circular diameter (Ecd) is the diameter 
of a circle that has the same area as a mitochondrion being 
measured. The formula for Ecd is: 
Ecd = 2 (Ap/3.14)l/2 
The two dimensional characteristics calculated for each 
mitochondria were averaged within each electron micrograph 
and analyzed as repeated measure of experimental unit (dog). 
The experiment was of complete random design used to 
compare groups of different treatments. Individual dogs were 
the experimental units. Analysis of variance was done 
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utilizing the computer based Statistical Analysis Systems 
(SAS Institute Inc., Gary, North Carolina). Least 
significant differences were calculated from the experimental 
error of dogs within groups (Snedecor and Cochran, 1967). 
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RESULTS 
The average daily sodium arsenite consumption per kg of 
body weight is shown in Table 1. Arsenite caused a 
statistically significant dosage dependent decrease in body 
weight. This decrease is described, in more detail elsewhere 
(Neiger and Osweiler, 1987a). Serum enzymes aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) but 
not alkaline phosphatase were significantly elevated by 
arsenite exposure, also described elsewhere (Neiger and 
Osweiler, 1987b). 
None of the livers had gross lesions at post-mortem 
examination. Liver weight per body weight of medium dosage 
group was significantly different from that of controls. Mean 
liver weight per body weight for control, low dosage, medium 
dosage, high dosage, and pair fed groups were 29, 27, 33, 31, 
and 29 gm/kg respectively. The least significant difference 
between groups was 3.8 (p=0.05). Therefore only the medium 
dosage group differed significantly from the control group. 
Light microscopy revealed no difference amoung groups. 
No lesions were found in any group on evaluation of 
hematoxylin and eosin stained sections. Hepatocyte glycogen 
content was abundant and not significantly different among 
control, medium dosage, high dosage, and pair fed groups. 
Hepatocyte lipid content was limited and not different 
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between control and high dosage groups. 
Hepatocyte mitochondrial volume density was 
significantly increased in the high dosage group (Table 2). 
However, the mitochondrial surface density was not 
statistically changed by arsenite exposure. Volume and 
surface densities of the hepatocyte nuclei, lysosomes, and 
fat globules did not differ significantly between control and 
high dosage groups (Tables 2 and 3). The number of 
mitochondrial profiles per reference area was not 
significantly different (p=0.72) between control and high 
dosage groups and were 0.25 and 0.24/um respectively. 
Three of the 2 dimensional characteristics of individual 
hepatocyte mitochondria were significantly changed by the 
treatment (Table 4). The perimeter and maximum diameter of 
mitochondria from the high dosage group were significantly 
increased (p=0.03 and 0.01 respectively). Circularity shape 
factor was significantly lowered in the high dosage group 
(p=0.01). Minimum diameter between groups was not 
statistically different (p=0.27). The area per mitochondria 
and équivalant circular factor were both increased in the 
high dosage group but not significantly (p=0.10). 
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DISCUSSION 
Serum enzymes AST and ALT were significantly elevated in 
high and medium dosage groups but not in the pair fed group 
(Neiger and Osweiler, 1987b). This gives evidence there is a 
direct effect of arsenic on the liver. All changes in 
treated groups must be interpreted in light of a highly 
significant dosage dependent decrease in feed intake and body 
weight (Neiger and Osweiler, 1987a). The high dosage group 
dogs lost, on average, approximately 20 percent of their 
initial body weight. 
Increase of medium dosage group liver weight per body 
weight was not paralleled by any other group leaving the 
cause of the increase undetermined. High dosage and pair fed 
groups had highly significant weight loss and no significant 
change in the liver weight to body weight ratio. Therefore, 
the liver weight loss was proportional to the body weight 
loss. Decrease of liver reserves is expected in chronically 
starved animals (Kelly, 1985). 
Mitochondrial volume density was increased and was the 
only sterologically measured parameter changed by arsenic 
treatment (Table 2). Increased mitochondrial numbers or size 
or both could cause this change. No change in the number of 
mitochondrial profiles per reference area suggests that the 
number of mitochondria per volume did not increase. 
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The ratios of number of mitochondria per hepatocyte 
volume and mean mitochondrial volume between high dosage and 
control groups can be approximated using the concept of 
diameters of equivalent spheres (Weibel, 1979). The diameter 
of an equivalent sphere is the diameter of a sphere with the 
same volume as the object of interest (mitochondria). There 
is some variation of the shape of mitochondria in this study, 
however the majority appear to be prolate ellipsoides. The 
average length to width ratio is less than 2 as estimated by 
the ratio of maximum diameter to minimum diameter. In the 
case of prolate ellipsoides with an eccentricity of 2, the 
difference between equivalent diameter and true mean diameter 
is only 9 percent (Weibel, 1979). Therefore, the error 
incurred by using diameters of equivalent spheres is less 
than 9 percent. 
The development of the calculations of the number of 
mitochondria per volume and mean mitochondrial volume ratios 
is as follows. The mean volume of a mitochondrion (V) equals 
its volume density (V^) divided by its numerical density 
(number of mitochondria per hepatocyte volume, N^). 
(1) V = Vp / 
It has been proven that numerical density of an object is the 
number of objects per area (N^) divided by the mean caliper 
diameter (D) of the object(Weibel, 1979). 
(2) Np = / 5 
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In this case the mean caliper diameter is the diameter of an 
equivalent sphere of the mitochondria. Using equations 1 and 
2 the ratio between mean mitochondrial volumes can be 
expressed. 
\ (W do)  
The subscript c indicates control group and h indicates high 
dosage group. Equation 2 can be substituted into equation 3 
to yield: 
<•" \ = (W^h) («Ah/^Ac) (V°h> 
where and are known. The volume of a sphere is: 
(5) V = 1/6 (3.14) 
Substituting equation 5 into equation 4 yields: 
(6) 1/6(3.14)D%/1/6(3.14)D\ = (N^/H^^) (D/D^) 
This equation can be solved for the ratio of the mean 
diameter of equivalent spheres of mitochondria for control 
and high dosage animals. 
<'' / 5h = [ (^Dc/^Dh) 
Using data from this study, the evaluation of this results 
in: 
(8) = [(0.139/0.169) (0.24/0.25) = 0.889 
From equation 7 and equation 2 the ratio of numerical 
densities can be found. 
("Do/^Dh) = 
Using data from this study, the evaluation of this results 
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in: 
(10) (^Dc/NDh) (0.25/0.24) (1/0.889) = 1.172 
The ratio of mean mitochondrial volumes of the control versus 
high dosage dogs can be found using equation 4. 
(11) Vg / = (0.139/0.169) (0.24/0.25) (0.889) = 0.702 
The mitochondrial numerical density ratio of 1.172 indicates 
the number of mitochondria per hepatocytic volume remained 
the same or slightly decreased in dogs treated with arsenic. 
The ratio of mean mitochondrial volumes of 0.702 indicates 
dogs treated with arsenic had enlarged mitochondria. 
Increases of mean area, perimeter, and maximum diameter 
of individual mitochondria also support the supposition that 
increased mitochondrial volume density is due to increased 
mitochondrial size (Table 4). However, the mean 
mitochondrial area increase of the high dosage group was not 
statistically significant with a p value of 0.11. 
Significant decrease in the mean circularity factor and 
increase of the mean maximum diameter suggest the 
mitochondria became elongated (Table 4). 
Two main ways mitochondria enlarge are by swelling or 
hypertrophy. Swelling involves the entry of solutes and 
water due to a defect in the osmotic homeostatic mechanisms 
(Cheville, 1983). Lack of ATP is a major cause of 
mitochondrial swelling. 
Inorganic arsenic as arsenite (trivalent) or arsenate 
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(pentavalent) can inhibit ATP production. Vahter (1983) 
reveiwed the literature and suggested that trivalent or 
pentavalent inorganic arsenic can be interconverted by in 
vivo metabolism. Rats injected with arsenite have the same 
hepatocytic mitochondrial metabolic alteration as rats given 
oral arsenate (Ghafghazi et al., 1980). Arsenate uncouples 
electron transport in the mitochondrial respiratory chain 
from oxidative phosphorylation (Squibb and Fowler, 1983). It 
also inhibits pyruvate dehydrogenase and/or its regulating 
enzymes presumably by binding to a critical phosphate binding 
site (Schiller et al., 1977; Schiller et al., 1978). 
Trivalent inorganic arsenicals like arsenite inhibit enzymes 
by binding to their sulfhydryl groups (Squibb and Fowler, 
1983). In mitochondria the critical enzyme pyruvate 
dehydrogenase is susceptible to inactivation by trivalent 
arsenic. Therefore, reduced amounts of ATP in treated 
animals is likely and could cause mitochondrial swelling. 
Mitochondrial hypertrophy develops in response to 
demands for energy, starvation or deficits of critical 
substrates, vitamins, and minerals (Cheville, 1983). 
Megamitochondria and/or reduplication and elongation of 
cristae are associated with hypertrophic mitochondria 
(Tandler and Hoppel, 1980; Riede et al., 1973). These 
changes were not obviously present in mitochondria studied. 
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However, more sensitive sterological techniques were not used 
to quantify mitochondrial internal membranes. Therefore a 
subtle change associated with hypertrophy cannot be ruled 
out. However, because of the lack of megamitochondria and/or 
reduplication or elongation of cristae, we conclude that 
mitochondrial enlargement is due to arsenic induced 
mitochondrial swelling. Evaluation of the pair fed group 
hepatocyte mitochondria should be done to confirm this 
conclusion. 
Starvation depletes liver stores of carbohydrates 
(Cheville, 1983; Kelly, 1985). In this study liver glycogen 
was highly conserved in all groups evaluated. The pair fed 
group dogs may have been better able to conserve the liver 
glycogen because they were older and weighed more. However, 
the high dosage group was very thin at termination and the 
presence of normal amounts of liver glycogen was unexpected. 
It is possible the glycogen was conserved in the high dosage 
group because of the blocking of its entry into the citric 
acid cycle by inactivation of pyruvate dehydrogenase by the 
arsenic. Another explanation would be if the high dosage and 
pair fed dogs converted primarily to lipid and ketone energy 
metabolism. This would allow what little glucose was taken 
in daily to be stored as glycogen. 
In conclusion liver mitochondria of dogs exposed to 
dietary arsenic were enlarged, elongated and had a greater 
150 
volume density than controls. Evidence presented supports 
the conclusion that mitochondrial enlargement is caused by 
arsenic induced swelling. These changes are similar to those 
found in rats exposed to sodium arsenate (Fowler et al., 
1979). 
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TABLE 1 . 
Average Daily Sodium Arsenite Dosage^ 
in Dogs Offered Contaminated Feed 
Groupé 
Control Low Medium High Pair Fed 
0.0 0.88 1.80 2.88 0.0 
0.0 1.66 2.87 3.74 0.0 
0.0 1.59 3.00 
Weeks 1-8 
Weeks 9-17 
Weeks 9-26 
^Dosage of sodium arsenite consumed in mg/kg of body 
weight. 
^Six dogs in each group. 
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TABLE 2 
Mean Volume Densities^ of Hepatocyte Ultrastructural 
Features of Dogs Offered Sodium Arsenite Contaminated Feed 
Control 
group 
High dosage 
group 
Pr>F^ 
Nuclei 0.041 0.061 0.30 
Fat globules 0.001 0.003 0.37 
Mitochondria 0.139 0.169 0.04 
Lysosomes 0.005 0.004 0.14 
a 3 3 Units are um /um . 
^Probability of a greater F value as determined by 
analysis of variance. 
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TABLE 3 
Mean Surface Densities^ of Hepatocyte Ultrastructural 
Features of Dogs Offered Sodium Arsenite Contaminated Feed 
Control 
group 
High dosage 
group 
Pr>F^ 
Nuclei 0.059 0.079 0.40 
Fat globules 0.007 0.016 0.26 
Mitochondria 1.005 1.119 0.28 
Lysosomes 0.037 0.030 0.33 
^Units are um^/um^. 
^Probability of a greater F value as determined by 
analysis of variance. 
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TABLE 4 
Mean Area, Perimeter, and Shape Indices 
of Individual Hepatocyte Mitochondria 
of Dogs Offered Sodium Arsenite Contaminated Feed 
Control 
group 
High dosage 
group 
Pr>F^ 
Area (um^) 0.55 0.70 0.11 
Perimeter (um) 2.86 3.30 0.03 
Circularity shape 
factor 0.76 0.74 0.01 
Maximum 
diameter (um) 1.01 1.19 0.01 
Minimum 
diameter (um) 0.67 0.72 0.27 
Equivalent circular 
diameter (um) 0.78 0.87 0.10 
^Probability of a greater F value as determined by 
analysis of variance. 
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SUMMARY AND DISCUSSION 
Dietary sodium arsenite causes a dose dependent decrease 
of feed consumption and body weight in dogs. Nominal dosages 
of 4 and 8 mg of sodium arsenite per kg of body weight per 
day (mg/kg/day) caused the decreases. After initial 
decreased feed consumption, feed intake slowly increased in 
all cases over time. Weight loss has been demonstrated 
previously in pigs, mice, rats, and dogs exposed to inorganic 
arsenic (Calvery et al., 1938; Byron et al., 1967; Fowler and 
Woods 1979; Morrison and Chavez, 1983). 
Nominal dosages of 1 and 2 mg/kg/day did not affect feed 
consumption or body weight. Dogs pair fed an amount of 
control feed that the high dosage group consumed also lost 
weight. Regression analysis of body weight demonstrated no 
significant difference between these groups. This proved 
weight loss is due to decreased feed consumption rather than 
a direct effect of arsenic. 
Serum liver leakage enzymes aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) were elevated in 
certain treated groups relative to controls. AST was 
elevated in dogs exposed to 4 and 8 mg/kg/day of sodium 
arsenite. ALT was elevated by a short term (6 weeks) 
exposure to 4 and 8 mg/kg/day and longer exposure (25 weeks) 
to 2 mg/kg/day. ALT and AST elevations relative to controls 
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were persistent and low grade. Only ALT in the high dosage 
group was elevated above what is considered normal as 
determined by Duncan and Prasse (1986). Elevated serum ALT 
and AST indicates sodium arsenite causes altered hepatocyte 
plasma membrane permeability. Accidental exposure of a dog 
to sodium arsenite in the field causes elevation of ALT 
(Evinger and Blakemore, 1984). 
The liver was examined grossly and with the use of light 
and electron microscopy. No gross or light microscopic 
lesions were present in any group. Electron microscopic 
examination of control group and high dosage group livers 
revealed a 22 percent increase of mitochondrial volume 
density in the treated group. Individual mitochondrial 
perimeters and maximum diameters were significantly increased 
in the high dosage group. Mitochondrial circularity shape 
factor was significantly decreased in treated animals. This 
study shows that dietary sodium arsenite in dogs causes 
enlargement of hepatocyte mitochondria. Evidence in this 
study supports the conclusion that the enlargement is arsenic 
induced swelling. Arsenic induced hepatocytic mitochondrial 
swelling has also been described in rats (Fowler et al., 
1979b). 
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Dose of anesthetic: 
If the animals are to be killed, identify the method of euthanasia: 
T-61 Euthanasia Solution , 
*In the event that anesthetizing the animal(s) will interfere with results of 
your proposed animal use, you may elect not to use an anesthetic. If you 
decide not to use an anesthetic, please attach your Justification for not 
using appjo^rl^te anesthetics when pain Is Involved. 
, • 
Department Executive Officer Date Investlga^r/Instructor Date 
(FOR OFFICE USE ONLY) 
ed Pi 
I ) Disapproved j J Disapproved Facilities: i Approv rotocol: L2J Approved 
Comments : ^ 
Ronald E. Flatt, D.V.M., Ph.D. Date 
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APPENDIX B. CLINICAL PATHOLOGY DATA 
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TABLE B1 
Serum Chemistry Values of Dogs 
Exposed to Dietary Sodium Arsenite 
Phase BUN^ CRT GLU TB DB AST^ ALT ALP ALB° 
Mean^ I 14 0.7 92 0.1 0.1 20 43 36 3.9 
S.E.® I 3.4 0.1 6 0 0 5* 44* 13 0.2* 
Mean Ila 15 0.8 90 0.1 0.1 21 43 31 4.1 
S.E. Ila 2.4** 0.1 8 0 0 7** 22** 20 0.4 
Mean lib 15 0.8 91 0.1 o
 
H
 
22 37 31 4.1 
S.E. lib 3.5 0.1 13 0 0 11** 22* 43 0.6 
^Values for BUN, CRT, GLU, TB, and DB are expressed 
in mg/dl. 
^Values for AST, ALT, and ALP are expressed in IU/1. 
^Values for ALB are given in gm/dl. 
^Overall mean. 
^Standard error = square root of mean square of dogs within 
groups. 
•k 
Probability of statistically significant differences 
among groups is greater than 95 percent. 
**Probability of statistically significant differences 
among groups is greater than 99 percent. 
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TABLE B2 
Serum Electrolyte Values of Dogs 
Exposed to Dietary Sodium Arsenite 
Serum Urine 
Phase NA® K CA^ P CL NA K CL P 
Mean° I 148 4.4 11 6.0 108 103 105 55 115 
S.E.d I 1.0* 0.2 0.2** 0.5** 1.4 49 37 27* 56 
Mean Ila 146 4.4 11 5.2 110 41 116 21 115 
S.E. Ila 2.6 0.3 0.6 0.7** 4.3 17** 55 18* 56 
Mean lib 146 4.4 11 5.2 111 62 107 35 91 
S.E. lib 1.6 0.3* 0.7* 0.8 2.2 49 42 31* 59 
^Values for Na, K, and CI are expressed in mEq/L. 
^Values for Ca and P are expressed in mg/dl. 
^Overall mean. 
'^Standard error = square root of mean square of dogs within 
groups. 
"k 
Probability of statistically significant differences 
among groups is greater than 95 percent. 
Probability of statistically significant differences 
among groups is greater than 99 percent. 
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TABLE B3 
NA, K, P, and CL Renal Percent Clearance Ratios^ 
of Dogs Exposed to Dietary Sodium Arsenite^ 
Phase PCRNA PCRK PCRP PCRCL 
Mean° I 0.33 10.7 8.5 0.23 
S.E.^ I 0.19 4.4 3.9 0.13 
Mean Ila 0.14 12.8 10.5 0.09 
S.E. Ila 0.09 8.2 5.8 0.10 
Mean lib 0.29 14.1 9.3 0.22 
S.E. lib 0.30 8.7 6.5 0.26 
^PCR 
^No statistically significant differences were present 
among groups in any phase. 
"^Overall mean. 
'^Standard error = square root of mean square of dogs within 
groups. 
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TABLE B4 
Hematological Values of Dogs 
Exposed to Dietary Sodium Arsenite 
Phase HGB PCV FIB TPP 
(gm/dl) (%) (mg/dl) (gm/dl) 
Mean^ I 16.7 48 133 6.3 
S.E.b I 1.1 3 29 0.2 
Mean Ila 16.1 47 178 6.3 
S.E. Ila 1.3 4 49** 0.3 
Mean lib 15.6 45 167 6.4 
S.E. lib 2.2 6 32 0.5 
^Overall mean. 
^Standard error = square root of mean square of dogs within 
groups. 
**Probability of statistically significant differences 
among groups is greater than 99 percent. 
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TABLE B5 
White Blood Cell Numbers of Dogs 
Exposed to Dietary Sodium Arsenite^ 
Phase I Phase Ila Phase lib 
Mean^ S.E.° Mean S.E. Mean •S.E. 
Total 9008^ 1991 8503 2308 8865 3763 
Band 
neutrophils 182 99 164 105 161 148 
Segmented 
neutrophils 5718 1734 5665 2112 6030 3445 
Lymphocytes 2564 643 2247 393 2270 612 
Monocytes 283 165 167 143 167 232 
Eosinophils 261 187 260 177 256 321 
^No statistically significant differences were present 
among groups in any phase. 
^Overall mean. 
*^Standard error = square root of mean square of dogs within 
groups. 
^Values given in number of cells per ul. 
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TABLE B6 
Urinalysis of Dogs 
Exposed to Dietary Sodium Arsenite 
Phase I Phase : Ila Phase lib 
Mean^ S.E.b Mean S.E. Mean S.E. 
Specific gravity 1.035 0.023 1.031 0.010 1.030 0.010 
Osmolality 
(mOsm/1) 
1112 333 1114 365 1014 346 
Urobilinogen 
(Ehrlich unit/dl) 
0.74 0.29 0.58 0.35 0.41 0.42 
Blood° 0.01 0.02 0.13 0.41 0.13 0.47 
Bilirubin 0.09 
* 
0.22 0.04 0.24 0.09 0.27 
Ketones (mg/dl) 0.26 0.80 0.89 1.50 0.91 1.90 
Glucose (gm/dl) 0.00 NA^ 0.01 0.01** 0.00 NA 
pH 7.35 0.66 7.03 0.68 7.31 0.69 
Protein (mg/dl) 11.6 14.4 14.7 13.3 14.4 23.0 
^Overall mean. 
^Standard error = square root of mean square of dogs within 
groups. 
^Blood and bilirubin were measured with a scale of 0, 0.1, 
1, 2, and 3 representing negative, trace, small, moderate, 
and large amounts respectively. 
^Not applicable. 
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APPENDIX C. PHOTOMICROGRAPH OF HEPATOCYTIC MITOCHONDRIA 
Fig. Cl. Photomicrograph of hepatocytic mitochondria from 
a dog of the control group. 15,890 X. 
Fig. C2. Photomicrograph of hepatocytic mitochondria from 
dog of the high dosage group. 15,890 X. 
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